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ABSTRACT
Previous abusive clinical trials have caused several obstacles in recruiting African
Americans for clinical trials today. The memory of the Tuskegee Syphilis Study alone
remains a hard pill to swallow and is a constant hindrance to recruiting potential African
Americans specifically males, for clinical trials. The basic trust that African Americans
have for physician researchers, U. S. government doctors, U. S. government-sponsored
research, and biomedical research in general has been seriously, although not irrevocably,
breached.
The purpose of this study was to gain an understanding of the knowledge, attitudes,
and beliefs African Americans have that support decisions to either participate or not
participate in a clinical trial. Specific areas that were examined by perceptual and demo
graphic measures included: knowledge of clinical research processes, perceptions of
clinical research purposes and procedures, advantages and disadvantages for the
individual of participation in clinical research trials, characteristics of current and past
participation in clinical research trials, exposure to selected experiences which are
preliminary to participation in clinical research trials, perceptions regarding the need for
selected changes in preparation for participation in clinical research trials; and selected
personal demographic characteristics: gender, age, marital status, education level,
employment status, household income, distance from research center, and overall health
status.
The survey method was utilized in this study. The discriminant analysis model was
used to determine if a model existed that significantly increased the researcher’s ability to
correctly classify volunteers on their participation status in clinical research trials. The
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overall model was meaningful and successful in correctly classifying 74.6% of the
original grouped cases.
The strongest findings suggest that African Americans are likely to participate in
future clinical trials based on their knowledge and perceptions of clinical research trials.
Principal Investigators and research teams which focus on African Americans in clinical
research trials should therefore place an increased emphasis on strategic planning that
involves participants representative of the study population. To yield results, the plan
should be tailored to African Americans, presented as a credible study, designed to
reflect trust in the medical care team, and implemented through a continuous educational
process.

xii
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CHAPTER 1
INTRODUCTION
Previous abusive clinical trials have caused several obstacles in recruiting African
Americans for clinical trials today. These past experiences, including those without
written protocols and uninformed consent, have left nothing but doubt, fear, and mistrust
among African Americans. The basic trust that African Americans have for physician
researchers, United States government doctors, United States government-sponsored
research, and biomedical research in general has been seriously, although not irrevocably,
breached (Thomas, Pinto, Roach, & Vaughn, 1994a). Modem clinical trials are designed
and monitored to safeguard against this type of abuse, however, the past effects of
government-sponsored racism do not dissipate quickly (Thomas et al„ 1994a). For this
reason, many obstacles of the past hinder the successful recruitment of African
Americans into clinical trials.
Some of the major obstacles experienced in the past by African Americans include
the Tuskegee Study of Untreated Syphilis. This study involved over 400 African
American farmers and was conducted by the United States Public Health Service from
1932 until 1972 (Jones, 1993). In this study African American men, with a diagnosis of
syphilis, were given no specific antisyphilitic treatment for 40 years in order to observe
the natural history of this infectious disease in a large cohort (Thomas et al.). Although
this study concluded approximately 28 years ago, it is still very prevalent in the minds of
African Americans today. The neglect and abuse of untreated syphilis for 40 years is a
hard pill to swallow, then and now. If the United States government betrayed the trust
o f African Americans over 40 years ago, what about today?
1
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Another obstacle from the past that deters African Americans from participation
in clinical trials occurred between 1845 and 1849 when J. Marion Sims, known as the
Father of American Gynecology, performed 42 operative procedures on African
American slave women in Montgomery, Alabama in search of a surgical cure for vesico
vaginal fistulas (Sims, 1852). Each of the three slave women underwent up to thirty
painful operations without the benefit of anesthetics. Postoperative medication consisted
o f opium at least twice in 24 hours (Allen, 1994). Consequently, these women were
eventually made drug addicts as a result of high doses of opium.
Other obstacles using vulnerable populations, or those who have insufficient
power, intelligence, resources, strength or other needed attributes to protect their own
interests through negotiations for informed consent (Levine, 1986) include gynecologic
and reproductive research that continued beyond the 19th century (Allen, 1994).
Between 1957 and 1958 Armand J. Pereyra, M.D., developed his needle urethropexy
procedure on inmates at the California Penal Institute for Women. The published report
presented results o f procedures performed on 31 inmates (Pereyra, 1959). The San
Antonio Contraceptive Study involved poor Mexican-American women enrolled in a
randomized, placebo-controlled, double-blind clinical trial designed to investigate the
side effects o f oral contraceptives (Levine, 1986). The women thought they were
receiving an active contraceptive; none were informed they would be receiving a placebo
(sugar pill). Because the trial involved a cross-over design, all participants received a
placebo for some part o f the trial. As a result, 11 of the 76 participants became pregnant
during the course o f the trial, 10 while on placebo (Levine, 1986).

2
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It is because of studies such as these and especially the Tuskegee Study, that
recruiting for clinical trials from the African American population is extremely difficult.
Remarks like: “you are not going to use me as a guinea pig” or, “what are they putting in
the food” and, “why are African Americans the only ones participating in this study”, are
just a few of the negative remarks a research recruiter encounters while trying to recruit
this population. The challenge in recruiting African Americans is even more crucial
because chronic disease disproportionately affects them and other minority populations
in the United States (Singh, Kochanek, & MacDorman, 1996). For example, this is
particularly true with hypertension, where the associated morbidity and mortality are
greatest among African Americans (Vollmer, Svetkey, Appel, Obarzanek, Reams,
Kennedy, Aicher, Charleston, Conlin, Evans, Harsha, & Hertert, 1998). The ageadjusted prevalence of hypertension in African American adults is 40 percent higher than
in Caucasian adults (Burt, Whelton, Roccella, Brown, Cutler, & Higgins, 1995). In
addition, mortality from blood pressure related cardiovascular diseases is 1.9 to 3.6 times
greater in African American adults aged 25-64 than in similarly aged Caucasian adults
(Singh etal., 1996).
The demand for proportionate representation of women, especially African
American women, in clinical trials is relatively recent. In fact, the textbook description
of a clinical trial calls for “homogeneous populations of patients” (Goodman & Gilman,
1990). Unfortunately, these homogeneous populations have been mostly white and
male. As a result, the National Institutes of Health (NIH) established guidelines for the
inclusion o f women and minorities and their sub-populations in its funded research with
human subjects (Federal Register, 1994).
3
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Federal funding agencies now require that all proposals and applications with
human subjects must include women and minority groups to improve gender and race
representation in clinical trials. These requirements specifically target under-represented
groups that are disproportionately affected by certain diseases (Kris-Etherton, Mustad,
& Lichtenstein, 1999).
Although there have been notable improvements in health status in the United
States over the past few decades, the picture of improved health status is not as impres
sive for African Americans and may have worsened in some cases (Braithwaithe and
Taylor, 1992). In 1985, the Report of the Secretary’s Task Force on Black and Minority
Health reported the wide disparity in health status between whites and African Ameri
cans (Unites States Department of Health and Human Services [USDHHS], 1985). The
report revealed that approximately 80,000 more African Americans than whites die each
year, and recent estimates indicate that the numbers continue to increase (Green,
Maisiak, Wang, Britt, & Ebeling, 1997). One of the wide disparities in health status
between whites and African Americans has been linked to factors associated with utiliza
tion o f health services.
Studies addressing the utilization rates of preventive health services by African
Americans have been conducted in a number of settings (Berkanovic & Telesky, 1985;
Caplan, 1992; Green et al., 1997; James, Wagner, Strogatz, Beresford, Kleinbaum,
Williams, Cutchin, & Ibrahim, 1984; Thomas & Quinn, 1991; Williams, LavizzoMourey, & Warren, 1994). The conclusions drawn in these studies indicate that there is
a need for a better understanding of underutilization of health services, including those
involving participation of African Americans in clinical research trials.
4
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Purpose o f the Study
The purpose of this study was to gain an understanding o f the knowledge,
attitudes, and beliefs African Americans have that support decisions to either participate
or not participate in a clinical trial.
Objectives
The following specific objectives were formulated to guide the researcher:
1.

To describe African Americans who were potential participants in clinical
research trials on each of the following perceptual and demographic measures:
a.

Knowledge of clinical research processes;

b.

Perceptions of clinical research purposes and procedures;

c.

Advantages and disadvantages for the individual of participation in
clinical research trials;

d.

Characteristics of current and past participation in clinical research trials;

e.

Exposure to selected experiences which are preliminary to participation in
clinical research trials;

f.

Perceptions regarding the need for selected changes in preparation for
participation in clinical research trials; and

g.

The following selected personal demographic characteristics:
i.

Gender,

ii.

Age,

iii.

Marital status

iv.

Education level,

V.

Employment status,
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2.

vi.

Household income,

vii.

Distance from research center, and

viii.

Overall health status

To describe and compare African Americans who have participated in clinical
research trials and those who have not participated in clinical research trials on
each o f the following perceptual and demographic measures:
a.

Knowledge of clinical research processes;

b.

Perceptions of clinical research purposes and procedures;

c.

Advantages and disadvantages for the individual of participation in
clinical research trials;

d.

Characteristics of current and past participation in clinical research trials;

e.

Exposure to selected experiences which are preliminary to participation in
clinical research trials;

f.

Perceptions regarding the need for selected changes in preparation for
participation in clinical research trials; and

g.

The following selected personal demographic characteristics:
i.

Gender,

ii.

Age,

iii.

Marital status,

iv.

Education level,

V.

Employment status,

vi.

Household income,

vii.

Distance from research center, and
6
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viii.
3.

Overall health status.

To determine if a model existed that significantly increased the researcher’s
ability to correctly classify volunteers on their participation status in clinical
research trials from the following perceptual and demographic measures:
a.

Knowledge of clinical research processes;

b.

Perceptions of clinical research purposes and procedures;

c.

Advantages and disadvantages for the individual of participation in
clinical research trials;

d.

Characteristics of current and past participation in clinical research trials;

e.

Exposure to selected experiences which are preliminary to participation in
clinical research trials;

f.

Perceptions regarding the need for selected changes in preparation for
participation in clinical research trials; and

g.

The following selected personal demographic characteristics:
i.

Gender,

ii.

Age,

iii.

Marital status,

iv.

Education level,

V.

Employment status,

vi.

Household income,

vii.

Distance from research center, and

viii.

Overall health status.

7
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Significance o f the Study
The success of a clinical trial is dependent upon the success of recruiting the
required number of volunteers. To gain an understanding of the knowledge, attitudes,
and beliefs African Americans have regarding clinical research trials is the first step in
obtaining useful information that will assist and guide researchers for future recruitment
o f African Americans. The results of this study should further assist researchers in
strengthening their recruitment efforts and strategies for increased participation of
African Americans in clinical research trials.
Limitation of the Study
This study is limited to African Americans who participated and those who did
not participate in a clinical trial at the Pennington Biomedical Research Center from
1992-2000. Since age, gender, and marital status are demographic characteristics
collected on all potential volunteers, the Chi-square statistical test was used to determine
if the respondents in this study were representative of the total population in the
Pennington Biomedical Research Center’s database. The Chi-square statistical test was
significant revealing that the respondents in this study were significantly different on the
examined characteristics from the total population as defined in the study.
However, it should be noted that even though the respondents in this study were
different from the population of the study on the examined characteristics, they were in
fact very similar to respondents in other studies of African American populations.
Specifically, the respondents had a higher percentage of married individuals than were
evident in the Pennington Biomedical Research Center’s population, but the percentage
o f married individuals was very similar to the results o f the study by (Appel, Vollmer,
8
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Obarzanek, Aicher, Conlin, Kennedy, Charleston, & Reams, 1999). Likewise, the
percentage of female respondents was higher than male respondents in this study and
very similar to the results of the study by Corbie-Smith, Thomas, Williams, & MoodyAyers, 1999). The highest percentage of respondents in this study were in the 46-55 age
group and similar results were found in studies by (Appel et al., 1999; Corbie-Smith, et
al., 1999; Green et al., 1997).
Definition of Terms
For the purpose and objectives of this study the following terms were operation
ally defined:
Clinical Trial: A clinical trial is a research study that can be used to answer questions
about vaccines or new therapies or new ways of using known treatments. Clinical trials
(also called medical research and research studies) are used to determine whether new
drugs or treatments are both safe and effective. Carefully conducted clinical trials are the
fastest and safest way to find treatments that work.
Informed Consent: Informed consent is the process of learning the key facts about a
clinical trial before deciding whether or not to participate. These facts include:
•

Why the research is being done.

•

What the researchers want to accomplish.

•

What will be done during the trial and for how long.

•

What risks are involved in the trial.

•

What benefits can be expected from the trial.

•

What other treatments are available.

•

And, the right to leave the trial at any time.
9
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Nonparticipant: Eligible volunteers who either chose not to participate or were ineligible
to participate in a clinical trial.
Participant: Eligible volunteers who chose to participate in a clinical trial.
Protocol: All clinical trials are based on a set of rules called a protocol. A protocol
describes what types of people may participate in the trial; the schedule of tests, proce
dures, medications, and dosages; and the length of the study. While in a clinical trial,
participants are seen regularly by the research staff to monitor their health and to deter
mine the safety and effectiveness of their treatment.

10
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CHAPTER 2
REVIEW OF RELATED LITERATURE
The review of related literature is divided into four sections. The first section
will discuss obstacles to recruiting African Americans in clinical trials. The next section
will discuss the importance of African American involvement in clinical trials. The third
section will discuss relevant, related literature. The final section will discuss researcher
biases that may have an impact on recruiting African Americans in clinical trials.
Obstacles to Recruiting African Americans in Clinical Trials
Historical Obstacles to Enrollment in Clinical Trials
There are many obstacles to the participation of African Americans in clinical
trials. Historically, medical research is viewed with suspicion among many African
Americans, and this creates a major hurdle. In perhaps the best known case of research
abuse, the United States Public Health Service began enrolling 400 black men, without
informed consent, into a natural history study of untreated, latent syphilis in 1932 (Allen,
1994). In 1946, it was reported that the death rate among those with syphilis was twice
as high as among the controls, yet the U.S. Public Health Service continued the study,
withholding treatment long after penicillin became available as standard therapy (Allen,
1994). It was not until the lay press exposed this in early 1970 that the study was inter
rupted (Jones, 1993). In another natural history study financed by the Army, mentally
retarded infants and children at the Willowbrook State School were deliberately infected
with hepatitis (Levine, 1986). In a recent study at the U niversity of California, Los
Angeles, schizophrenics were reportedly taken off their medication to determine what

would happen. The “informed consent” offered little detail of possible consequences.
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One of the subjects committed suicide after his family tried in vain to have his medication
reinstated (Allen, 1994). In fact, 32 o f 50 patients in the study suffered severe relapses.
Some authors have expressed concern that racial minorities might be over-represented in
general in clinical trials (El-Sadr & Capps, 1992). Levine (1986) stated, “The inner-city
location of many university hospitals is problematic in that it increases the likelihood of
disproportionate use of racial and ethnic minorities as well as impoverished people as
research subjects.” Stevenson, 1989 addressed this concern by reviewing the representa
tion of African Americans in studies published in 1984, 1985, and 1986 in Clinical Phar
macology and Therapeutics. He found that in the majority of these studies, the propor
tion of African American participants was less than their proportion in the general
population.
Traditionally, the recruitment of a patient for a clinical trial involves primarily the
provision of information regarding the specifics of the trial prior to obtaining informed
consent. However, for the patient who has no previous conception of a clinical trial,
successful recruitment requires an extensive educational effort. This education must
include an explanation of the meaning of a trial, random sampling, the nature of blinding,
and the concept of a placebo, and a description o f the responsibilities of the provider and
the participant, among other information (El-Sadr & Capps, 1992). It is not until after
the volunteer has a complete understanding of these issues that the specific protocol can
be discussed. This is a time-consuming process that requires educational skills, patience,
and the building of trust. It also requires the availability o f creative and appropriate
educational materials. Often the widely available educational materials are not suitable
for the patient who has not had an extensive education (El-Sadr & Capps, 1992).
12
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Poor, often minority, patients have traditionally sought care at their neighbor
hood institutions. They are reluctant to travel or to accept referral to unfamiliar institu
tions and providers. Thus, one of the most important barriers to their recruitment has
been the fact that, until recently, few of the trials were conducted at institutions where
many of these patients receive their primary care. The ability o f the primary care provid
er to explain the clinical trial to his or her patient is more likely to overcome mistrust and
reluctance, and the fact that the patient does not have to travel to another institution to
participate in a trial may facilitate recruitment ((El-Sadr & Capps, 1992).
Socio-cultural Obstacles to Enrollment in Clinical Trials
The many social needs o f minority volunteers often hinder their ability to partici
pate in clinical trials. These issues are seldom addressed or funded by sponsors of
clinical trials. Often the primary interests of sponsors are the rapid completion of the
trial and maximum adherence at minimum cost. Many volunteers are homeless, active
drug users, and many are women with young children. In addition, volunteers have
limited income and lack resources for associated transportation, food, and nutritional
supplements (El-Sadr & Capps, 1992). Thus, successful recruitment and, even more
important, adherence to protocol visits are dependent on more than just providing the
study drug. Successful recruitment and volunteer adherence depend on the availability of
a social worker to provide advice on housing, substance abuse programs, and other
services. They also depend on providing child care, convenient transportation, and a
warm meal during visits (El-Sadr & Capps, 1992). The importance o f a participant
advocate who can track down volunteers and assist them in making protocol related
visits is critical.
13
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Other prevailing socio-cultural obstacles include racial and ethnic discrimination
(Blendon, Scheck, Donelan, Hill, Smith, Beatrice, & Altman, 1995; El-Sadr & Capps,
1992; Freeman, 1989; Hutchinson, 1992; Swanson & Ward, 1995; Thomas et al., 1994a;
Thomas, Quinn, Billingsley, & Caldwell, 1994b) and cultural beliefs about specific
diseases or illness in general (Ballard, Nash, Raiford, & Harrell, 1993; Bennett, 1993;
Freeman, 1993; Groce & Zola, 1993; Kaluzny, Brawley, Garson-Angert, Shaw, Godley,
Wamecke et al., 1993; and Swanson & Ward, 1995). There is widespread fear and
mistrust of the medical care system among various minority populations as a result of
indifference and disrespect exhibited by some health care professionals toward those who
are socio-economically disadvantaged (Freeman, 1993; Haynes & Bernard, 1992;
Kaluzny et al., 1993; McCabe, Varricchio, & Padberg, 1994; Swanson & Ward, 1995; &
Wray, 1992). Minorities have been devalued by the health care system, and their
illnesses often have been labeled as deviance (Blendon et al. 1995; El-Sadr & Capps,
1992; Hutchinson, 1992; Swanson & Ward, 1995). In addition, general racial
discrimination and segregation in our society produce fear and mistrust of federally
sponsored projects, academic medicine, and clinical research (Nickens, 1990; Swanson
& Ward, 1995 & Thomas et al., 1994a; Thomas et al., 1994b). Finally, differences in
health beliefs and health behaviors also influence the potential for clinical trial participa
tion. For example, some African American, Hispanic, and rural populations are more
likely to delay seeking medical treatment and to under utilize preventive care, resulting in
higher levels of presentation with later stage cancers (Durant, Ashworth, Newman,
McGill, Raban*& Baranowski, 1992; Freeman, 1993; Swanson & Ward, 1995; Wray,
1992).
14
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Economic Obstacles to Enrollment in Clinical Trials
The impact of socioeconomic status on health and use of medical services is
receiving increased attention (Dutton & Levine, 1989; Epstein, Stem, Tognelti, Begg,
Hartley, Cumella, & Ayanian, 1988; Feinstein, 1993; Rask, Williams, Parker, &
McNagny; Adler, Boyce, Chesney, Folkman, & Syme, 1993). Recent studies have
shown that insurance coverage alone does not guarantee use of timely and appropriate
medical care (Dutton, 1978; Pappas, Queen, Hadden, & Fisher, 1993; Riportella-Muller,
Richardson, Luchok, Donat, & Selby-Harrington, 1993; S t Peter, Newacheck, &
Halfon, 1992; Savitz & Ricketts, 1993). Other economic obstacles faced by indigent
volunteers include out-of-pocket medical expenses; lack of sick leave, child care costs,
and lack of transportation (Kiefe & Harrison, 1993; Riportella-Muller et al., 1993; Savitz
& Ricketts, 1993). Health care system and organizational barriers that are particularly
likely to affect minority populations include availability of public health care facilities,
lack of providers for Medicaid, and geographic accessibility of ambulatory care
(Riportella-Muller et al., 1993; Savitz & Ricketts, 1993; Yudkowsky, Cartland, & Flint,
1990).
Additional specific or enabling factors can include language barriers, educational
deficits, health beliefs, and dysfunctional social or home environments (Feinstein, 1993).
Minority populations are also more likely to experience adverse environmental and social
conditions, such as crime and violence, that hamper their ability to modify health-dam
aging behaviors and obtain adequate care (Adler et al., 1993; Dutton & Levine, 1989;
Feinstein, 1993). If these economic, structural, and cultural factors are significant barri
ers to medical care, they may result in delays in seeking care and adverse health
15
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outcomes independent of health insurance status (Shea, Miara, Ehrlich, Field, & Francis,
1992; Weissman, Stem, Fielding, & Epstein, 1991).
The overwhelming economic obstacles to the participation of many minority
populations in clinical trials is lack of access to health care in general (Blendon et al.,
1995; DuRant et al., 1992; Elks, 1993; Elks, Short, Cornelius, & Goldstone, 1990;
Freeman, 1993; Kindig & Yan, 1993; Murdaugh, 1990; Reis, Sherman, & Macon, 1989;
Swanson & Ward, 1995; Walker, Lucas, & Crespo, 1994; Wray, 1992). Lack of health
insurance is a critical factor that limits access to health care among low-income, minority
populations (Short et al., 1990; Swanson & Ward, 1995). The poor quality o f general
health services available in some African American and other low-income communities is
another important factor that limits access to health care, thus to clinical trials (Blendon
et al., 1989; Freeman, 1989; Kindig & Yan, 1993; Swanson & Ward, 1995, Wray,
1992). There is evidence that rural and elderly m inority populations are subsets of
minorities that have least often been included in clinical trials (Kindig & Yan, 1993;
Swanson & Ward, 1995; Wray, 1992).
It is very difficult to unravel the effects of poverty on clinical trials participation
from those issues related to race and ethnicity (Ballard et al., 1993; Blendon et al., 1989;
Freeman, 1989; Freeman, 1993; Lacey, 1993; Nickens, 1990; Swanson & Ward, 1995;
Thomas et al., 1994b). It is well recognized that poverty is a leading risk factor for
cancer and other diseases (Freeman, 1989; Kindig & Yan, 1993; Swanson & Ward,
1995). The effects of poverty are extensive, ranging from dangerous living environments
to poor nutrition and inadequate housing; to unemployment, financial instability, and
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inability to obtain public assistance; to lack of telephones and transportation (Ballard et
al.,1993; Blendon et al., 1989; Lacey, 1993; Swanson & Ward, 1995).
Obstacles Inherent in Study Design
Minority health care professionals are raising important issues about restrictive
exclusion criteria. They indicate that entire segments of the population are effectively
banned from obtaining the benefits of clinical trials, including improved medical care,
better quality of life, longer survival, and access to compensation that accompanies some
studies (Elks, 1993; El-Sadr & Capps, 1992; Jimenez & Jimenez, 1992; MiltonUnderwood, Sanders, & Davis, 1993; Swanson & Ward, 1995). Differences in drug
response and in other outcomes across diverse ethnic groups and by sex further prolong
the problems resulting from limited access to clinical trials among these groups (Crews
and Bindon, 1991; El-Sadr & Capps, 1992; Merkatz, Temple, Subel, Feiden, & Kessler,
1993; Milton-Underwood et al., 1993; Swanson & Ward, 1995).
Complexity of forms and procedures also inhibit participation o f many popula
tions (Elks, 1993; Haynes & Bernard, 1992; Kaluzny et al., 1993; McCabe et al., 1994;
Swanson & Ward, 1995; Freeman, 1993; Wray, 1992;). Forms used to ensure informed
consent are a good example of this problem, as most of them are well above the reading
level of some populations, may not explain the benefits of the trial, may not explain that
care given as routine is not very effective, or may actually induce fear if they are too
complex (Elks, 1993; Haynes & Bernard, 1992; Swanson & Ward, 1995).
Importance of African Americans Involvement in Clinical Trials

Chronic disease disproportionately affects African Americans and other minority
populations in the United States (Singh et al., 1996) and therefore, the need to enroll
17
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African Americans into clinical trials is necessary to reduce this disparity. It is important
for African Americans to participate in clinical trials because of the potential to identify
effective prevention, and treatment strategies for many of the health conditions that
afflict them. Yet, African Americans and other minorities do not participate in clinical
trials in numbers proportional to their risk of disease (Thomas et al., 1994a). Since race
can affect disease severity, progression, and response to drug therapy (Matthews, 1995),
under-representation of African Americans and other ethnic minorities in clinical trials
will decrease the ability to generalize study results to minority populations.
More specifically, applicability of findings would be questionable for the various
racial/ethnic groups as documented by the National Cancer Institute (NCI). For
example, the severity of the cancer problem among racial/ethnic populations compared
with that among the general population is such that timely, definitive data are critical to
improve cancer survival rates and reduce treatment side effects (Pickle, Mason, Neil,
Hoover, & Fraumeni, 1990; Roberson, 1994). Results from clinical trials would be
useful to determine the efficacy of treatments for sites where cancer rates are high for the
various racial/ethnic groups compared with the general population.
For almost all health care problems, morbidity and mortality rates are substan
tially higher for the ethnic minority group than for the non-minority population
(Raczynski, 1997). The mortality rates for African Americans in most all age levels for
both males and females exceed those of whites with some o f these rates double or more
(Raczynski, 1997). While income and other benefits that go along with income are
factors accounting for excess disease outcomes for African Americans, about one-third
o f the excess mortality in one analysis was accounted for by risk factors, suggesting a
18
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greater importance for African Americans across the country lies in learning better
methods of preventing disease outcomes (Otten, Teutsch, Williamson, & Marks, 1990).
Relevant Related Literature
Clinical trials play a dominant role in clinical oncology today (Devita, Heilman,
& Rosenberg, 1989). Despite the state-of-the-art cancer treatment, however, there is
mounting concern that the benefits of this medical and scientific progress is not being
equitably shared by or distributed to all segments of the U.S. population (Byrd & Clay
ton, 1992).
The fact that racial/ethnic groups are under-represented in cancer clinical trials is
supported by a review of literature that showed that very few volunteers, and in most
cases no racial/ethnic volunteers, are enrolled in clinical trials (Byrd & Clayton, 1992;
Roberson, 1994). Under-representation was further evident in the Clinical Trials
Program of the NCI, in which recruitment efforts yielded low volunteer accrual since the
initiation of the program in 1955 (Meinert & Tonascia, 1986; Roberson, 1994). It was
not until 1990 that the NCI directed specific attention to the problem o f low
participation o f racial/ethnic volunteers. Through its Minority Community Clinical
Oncology Program, the NCI sought to improve volunteer accruals primarily through
historically minority colleges and institutions (Byrd & Clayton, 1992).
Under-representation of racial/ethnic volunteers in cancer clinical trials also sur
faced and became a critical issue during the Congressional Hearings 1992 on the NCI
Breast Cancer Prevention Trial (BCPT). Among one of the key issues was the failure to
address the recruitment of adequate numbers of racial/ethnic women for participation in
the study. Within a 2-year period, fewer than 2% of minority women were enrolled
19

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

(Payne, 1992). No strategic plan was in place to include these women or improve
accrual rates.
Researchers at the Pennington Biomedical Research Center (Baton Rouge,
Louisiana) have also experienced several obstacles in recruiting African Americans for
clinical trials. One of the specific research studies that had major obstacles was known
as the Estrogen Patch Study for women who were postmenopausal and Type II diabetic.
The goal was to recruit 70 African American women however, 18 enrolled, and only 15
(4 Caucasians and 11 African Americans) completed the one-year study. The purpose of
the study was to determine if risk factors for heart disease could be improved, whether
or not body composition and fat distribution could be altered, and if the ability of the
body to deal with the sugar in the blood could be improved using a hormone patch. Half
of the women received an active hormone patch while the other half received a placebo
(non-active hormone patch).
Another study that had difficulties in recruiting African Americans was Dietary
Approaches to Stop Hypertension (DASH). DASH was a national multi-center trial
sponsored by the National Lung and Blood Institute (Bethesda, Maryland). The study
was conducted at the Pennington Biomedical Research Center and 4 other Centers:
Duke University (Durham, North Carolina), Brigham and Women’s Hospital (Boston,
Massachusetts), Johns Hopkins University (Baltimore, Maryland), and Kaiser
Permanente Coordinating Center (Portland, Oregon). The task for the Pennington
Center was to recruit 100 percent African Americans while the other centers had goals of
either 50 percent other/50 percent minority or 60 percent other/40 percent minority.
DASH was an eleven-week feeding study that required volunteers to eat the dinner meal
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at the Center and all other meals (breakfast, lunch, and snacks) packed to go. In
addition, volunteers earned $600 after completing the eleven-week study.
Although hypertension is a disease that disproportionately affects African
Americans, the obstacles faced in recruiting them for the DASH trial was a challenge.
Some o f the challenges included rescheduling appointments, changed their minds, or they
did not show up for original or rescheduled appointments. Other challenges included
what they were saying about the trial such as: “why are you only recruiting African
Americans”, or “what are they putting in the food”, or “ I do not eat my food cooked
like that”, and finally, “what are they doing with my blood”. To try and alleviate some of
these obstacles, strategies must be established to gain trust among African Americans.
One way to gain trust was to participate in the clinical trial so that potential participants
would feel more at ease. However, gaining trust by participating in the trial may not be
enough especially when the majority of other staff members (Principal Investigator, CoPrincipal Investigators, Medical Director, Clinic Supervisor, Nurses, Dietitians, and
Research Associates) having direct contact with this targeted group were non-African
American. Although the goal was to enroll 100 percent African Americans in the DASH
study, permission was granted to enroll 10 Caucasians and Other to complete the trial
with the required number o f participants.
Other studies with obstacles in recruiting African Americans at the Pennington
Center included: DASH2 (Fourteen-week feeding study), Diabetes Prevention Program
(Six-year on-going intervention/drug trial), and Healthy Transitions (Four-year longitudi
nal study of perimenopausal women). The goal of the Healthy Transitions study for
example, was to recruit SO percent African American and SO percent Caucasian women
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and observe them before, during, and after menopause. However, out of 183 women
recruited, only 42 or 23 percent were African American.
Currently, there are two clinical trials at the Pennington Biomedical Research
Center requiring 100 percent African American participants. The first study, Maternity
Obesity Management Study (MOMS) is a study for females age 16 and over who gained
v

'

and retained an excess of 25 pounds or more of weight after delivery of their baby, and
had no complications during pregnancy such as gestational diabetes. The recruitment
goal of the study was to have 56 volunteers enrolled by March 2001. As of February
2001 all 6 volunteers previously enrolled had dropped out of the study. Despite many
recruitment efforts such as: TV appearances, radio (live talk show), flyers and luncheons
taken to physician offices, flyers in pediatric clinics, day care centers, beauty shops, and
several other medical and non-medical entities, African American women who had
scheduled appointments did not show up and/or rescheduled appointments, did not show
up. The principal investigator therefore, requested permission from NIH and it was
granted, to extend recruitment to all females meeting the study criteria.
The second study currendy being recruited is the Health Improvement Programfor Teens (HIP-Teens). This study is for overweight African American girls age 11-15
with at least one overweight parent. The goal is to recruit 60 families using the Internet
to interact with both groups to prevent weight loss through either behavioral change or
nutritional education. There are 12 families currently enrolled with another 48 required
to meet the recruitment goal of the study.
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Researcher Biases
Some of the obstacles that result from researcher bias are frequently viewed by
the researchers as obstacles that are due to the individuals or populations to be recruited
into clinical trials (DuRant et al., 1992; Freeman, 1993; Haynes & Bernard, 1992;
Jimenez & Jimenez, 1992; Nelson, 1994; Swanson & Ward, 1995; Wermeling & Selwitz,
1993). The biases of researchers and clinical investigators include failure to
accommodate cultural and economic diversity of potential study participants, failure to
recognize that restrictive studies do not fully assess safety and efficacy of new treatments
or preventive interventions for all populations, claims that statistical power will be
reduced if women and minorities are included, inaccurate beliefs that certain populations
are not at risk for specific conditions or illnesses, and failure to establish research clinics
in minority institutions (DuRant et al., 1992; Freeman, 1993; Jimenez and Jimenez, 1992;
Lacey, 1993; Swanson & Ward, 1995; Wermeling & Selwitz, 1993).
Finally, one of the most common excuses for not including minorities in preven
tion and treatment trials is that they are “hard to reach” (Lacey, 1993; Swanson & Ward,
1995). This is the typical example of researcher insensitivity and discrimination: the
population is defined as difficult and problematic, conveniently ignoring the fact that it is
the life conditions of these populations that are problematic; not the people (Swanson &
Ward, 1995).
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CHAPTER 3
METHODS AND PROCEDURES
The purpose of this chapter was to describe the procedures used in the study,
including sampling, data collection, and data analysis. These procedures were used to
address the purpose of the study: to gain an understanding of the knowledge, attitudes,
and beliefs African Americans have that support decisions to either participate or not
participate in a clinical trial.
Population and Sample
The target population was defined as all African Americans age 18 and older who
were potential participants in a clinical trial. The accessible population were all African
Americans in the Pennington Biomedical Research Center Database from 1992-2000.
The frame of the accessible population was established as those who were currently
enrolled at the time of the study, previously participated, and those who did not
participate in a clinical trial. The sample consisted of 100% of the defined accessible
population frame.
Instrument
A modified version of the questionnaire (Appendix B) “Perceptions of Participation in
Clinical Research” (McLean & Jensen, 1998) was utilized in conducting this study.
Permission to modify and utilize the original questionnaire was granted in writing by the
authors (Appendix C). The original questionnaire was modified due to the relevance of
questions applicable to African Americans, length of the instrument, and the approximate
time it would take to complete.
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The modified version of the questionnaire consisted of 8 pages, 58 questions, and
7 sections. The first section consisted of 7 items to measure knowledge of clinical
research processes, section two consisted of 8 items to measure perceptions of clinical
research purposes and procedures, section three contained two parts: advantages (8
items and other) and disadvantages (6 items and other) for the individual of participation
in clinical research trials, section four consisted o f 6 questions to examine the
characteristics o f current and past participation in clinical research trials, section five
contained 4 items to determine the exposure to selected experiences which are
preliminary to participation in clinical research trials, section six contained 6 choices and
other to measure the perceptions regarding the need for selected changes in preparation
for participation in clinical research trials, and section seven consisted of 8 selected
personal demographic characteristics including gender, age, marital status, education
level, employment status, household income, distance from research center, and overall
health status. Participants were assured of confidentiality and that there were no right or
wrong answers in completing the survey instrument. The questionnaire began with the
definition o f a clinical trial and instructions for completion.
The original instrument from which the study instrument was adapted had been
validated by expert panels. Because modifications were made for the purpose of the
current study, a validity assessment for the study instrument was needed. Face validity
o f the instrument was established through a review by three professors at Louisiana State
University (three from the School of Human Resource Education and Workforce
Development, two active and one emeritus), and one professor from the Biostatistics
Department, Pennington Biomedical Research Center.
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Reliability of the instrument was assessed in September 2000 by conducting a
field test with African Americans who were not a part of the study, but similar to those
in the target population. The purpose of the field test was to determine what kind of
feedback to expect from African Americans who would respond to the questionnaire in
this study. Based on a favorable response from African Americans in the field test, the
researcher concluded the questionnaire favorable for potential respondents in this study.
Reliability of the scaled response sections of the instrument was estimated using
Cronbach’s Alpha internal consistency coefficient. This included sections I, II, III, and
VI o f the modified questionnaire.
The Cronbach’s Alpha internal consistency coefficients were as follows:
Scale

Number of items

Cronbach’s Alpha

Section I - Knowledge

7

.78

Section II - Perceptions

8

.81

Section m - Part I Advantages

8

.83

Section III - Part II Disadvantages

6

.85

Section VI - Ideas/Suggestions

6

.83

Data Collection
The questionnaire was mailed to 3302 African American adults (770 participants
and 2532 nonparticipants) who were potential participants in a clinical trial at the
Pennington Biomedical Research Center during the years of 1992-2000. A total of 117
questionnaires (49 participants and 68 nonparticipants) were returned undeliverable.
Since the addresses in the database for participants and nonparticipants were up to 8
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years past, the researcher believed that many participants and nonparticipants did not
respond because they had moved and the forwarding order had expired.
Labels were printed and addressed to each participant and nonparticipant in the
Pennington Biomedical Research Center database from 1992-2000. Questionnaires were
mailed along with a self-addressed stamped envelope. A letter of introduction (Appen
dix A) accompanied the questionnaire. Along with instructions and guidelines, the letter
stressed the importance of completing the survey. The questionnaires were coded by
seven digits of non-repeated random numbers to allow follow-up for unretumed
questionnaires. Participants were asked to return questionnaires within two weeks after
receiving.
After the third week, questionnaires began to decrease in numbers and
immediately follow-up began and continued for one month and nine days. Follow-up
included calling and reminding potential participants that it was not too late to return
questionnaires. Some questionnaires came back with a new address and they were resent
locally as well as to those who had moved out-of-state. Some respondents completed
and dropped-off questionnaires to the researcher at the Pennington Biomedical Research
Center. A total o f386 (158 participants or 21 percent, and 228 nonparticipants or 9
percent) responded to the questionnaire.
Data Analysis
Data collected in this study was analyzed using the following procedures for each
respective study objective:
•

Objective one was to describe African Americans who were potential
participants in clinical research trials on (a) knowledge o f clinical research
27
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processes, (b) perceptions of clinical research purposes and procedures,
(c) advantages and disadvantages for the individual of participation in
clinical research trials, (d) characteristics of current and past participation
in clinical research trials, (e) exposure to selected experiences which are
preliminary to participation in clinical research trials, (f) perceptions
regarding the need for selected changes in preparation for participation in
clinical research trials, and (g) selected personal demographic characteris
tics to include: gender, age, marital status, education level, employment
status, household income, distance from research center, and overall
health status.
The researcher used descriptive statistics (frequency, percentage, mean, standard
deviation, range) and factor analysis for objective one. Sections one, two, three, and six
of the instrument was collected as continuous (interval data). Sections four, five, and
seven was collected as categorical (nominal and ordinal data).
•

Objective two was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated
in clinical research trials on each o f the items in objective one listed
above. An alpha level of .05 was used to determine significance through
out the study.

To describe the groups, the researcher used descriptive statistics (mean, standard
deviation) and factor analysis for objective two. To compare the groups, the researcher
used the independent samples t-test procedure and Chi-square statistical techniques as
applicable.
28

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

•

Objective three was to determine if a model existed that significandy
increased the researcher's ability to correcdy classify volunteers on their
participation status in clinical research trials on each of the items in
objective one listed above.

The researcher used discriminant analysis to accomplish objective three.
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CHAPTER 4
FINDINGS
Knowledge of Clinical Research Processes
Findings presented in this chapter are organized by objectives of the study. The
first objective was to describe African Americans who were potential participants in clin
ical research trials on their level of knowledge of clinical research processes. To
measure the level of knowledge of clinical research processes, a seven item scale was
used. The response scale utilized was a five-point Likert-type scale with values ranging
from 1 = “Strongly Disagree” to 5 = “Strongly Agree”. The middle point (3) on the
scale did allow the respondents the option of an “Unsure” answer. To aid in the
interpretation of this data, the researcher established an interpretive scale based on the
responses available to the study participants. This scale had descriptions and
corresponding values as follows: 1.00 to 1.50 = “Strongly Disagree;” 1.51 to 2.50 =
“Disagree;” 2.51 to 3.49 = “Unsure;” 3.50 to 4.49 = “Agree;” and 4.50 to 5.00 =
“Strongly Agree.”
When the data from the responses to the seven statements on the scale were
examined, the statement with which the respondents most strongly agreed was,
“Volunteers can refuse to participate in a clinical trial” (mean = 4.61, SD = .67). This
statement was classified using the interpretive scale as “Strongly Agree”. The statement
with which participants least agreed was, “Volunteers usually receive a cash stipend for
participation in a clinical trial” (mean = 4.00, SD = .89). The mean response to this
statement was classified in the “Agree” category. Overall, one statement in this scale
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was classified as “Strongly Agree,” and six statements were classified as “Agree” (see
Table 1).
Table 1
Level o f Knowledge of Clinical Research Trials of Potential African American
Participants
Mean*

SD

Classification11

Volunteers can refuse
to participate in a
clinical trial.

385c

4.61

.67

Strongly Agree

Clinical trials are
needed to study the
effects of treatments.

385c

4.46

.68

Agree

Volunteers can change
their mind at any time
and withdraw from a
clinical trial.

384d

4.20

.98

Agree

Volunteers receive
information needed to
decide whether they
want to take part in a
clinical trial.

un
00
CO

4.10

1.03

Agree

4.08

.98

Agree

4.02

1.01

Agree

Volunteers are told
about the possible risks
and benefits of taking
part in a clinical trial.

386

o

00
CO

Volunteers are made
aware o f any possible
complications or side
effects of taking part in
a clinical trial.

o

n

Item

(Table continues)
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o
00

.89
4.00
Agree
Volunteers usually
receive a cash stipend
for participation in a
clinical trial.
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly
agree.
'’Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
cOne respondent did not answer this item.
dTwo respondents did not answer this item.
To further summarize the information regarding level of knowledge of clinical
research processes, the researcher used factor analysis to determine if underlying con
structs could be identified in the scale. The analysis procedure used was principal com
ponents analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum
number of factors to be extracted from the scale. Using a combination o f the latent root
criterion, and the scree test criterion, the number of factors to be extracted was deter
mined to be two. The results of the factor analysis including the factor, it’s label based
on the content of the items included in the factor, the percentage of variance explained
by each factor, and factor loadings for each of the statements in each of the factors is
presented in Table 2. The two sub-scales were labeled by the researcher as “Information
Provided,” and “Awareness.” The first factor identified in the scale was information
provided that related to knowledge of clinical research processes. Items in this factor
included, “Volunteers are told about the possible risks and benefits of taking part in a
clinical trial”, “Volunteers are made aware of any possible complications or side effects
o f taking part in a clinical trial”, “Volunteers receive information needed to decide

32

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

whether they want to take part in a clinical trial," and “Volunteers usually receive a cash
stipend for participation in a clinical trial." The factor loadings ranged from a high o f .90
to a low of .57 and explained 35.8 percent of the overall variance in the scale.
The second factor explained an additional 24.7 percent of the overall scale vari
ance and included items related to awareness of clinical research processes. Items in this
factor included, “Volunteers can change their mind at any time and withdraw from a
clinical trial”, “Volunteers can refuse to participate in a clinical trial,” and “Clinical trials
are needed to study the effects o f treatments." The factor loadings ranged from a high of
.83 to .48.
Table 2
Factor Analysis o f Level o f Knowledge of Clinical Research Trials of Potential African
American Participants
Factor-Information
Provided
(35.8% of variance
explained)

Factor I

Factor 2

Volunteers are told about
the possible risks and
bene- fits of taking part in
a clinical trial.

.90

.08

Volunteers are made
aware of any possible
complications or side
effects of taking part in a
clinical trial.

.86

.07

Volunteers receive infor
mation needed to decide
whether they want to take
part in a clinical trial.

.64

.32

(Table continues)
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Volunteers usually receive
a cash stipend for
participation in a clinical
trial.

.57

.31

Factor-Awareness
(24.7% of variance
explained)

Factor 1

Factor 2

Volunteers can change
their mind at any time and
withdraw from a clinical
trial.

.02

.83

Volunteers can refuse to
participate in a clinical
trial.

.25

.77

Clinical trials are needed to
study the effects of treat
ments.

.40

.48

After the two sub-scales and items to be included in each were identified, the
researcher computed scale scores for each of the two identified sub-scales. These sub
scale scores were identified as the mean of the items included in each of the respective
factors. For the first scale labeled “Information Provided,” the individual subject mean
scores ranged from a low of 4.00 to a high of 4.10 with an overall mean of 4.05 (SD =
.76). Using the interpretive scale, this scale received an overall rating classified as
“Agree.” The second scale was “Awareness,” and had individual subject means that
ranged from 4.20 to 4.61. The overall mean score was 4.42 (SD = .58) which was
classified in the “Agree” category. When the sub-scale scores were examined, the factor
which received the highest mean score was the “Awareness” sub-scale (mean = 4.42, SD
= .58) (see Table 3).
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Table 3
Knowledge of Clinical Research Trials Sub-Scale Scores of Potential African American
Participants
Sub-Scale

Items

Mean*

SD

Classification6

Range

Awareness

3

4.42

.58

Agree

4.20-4.61

4.00-4.10
4
4.05
.76
Agree
Information
Provided
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure; 4 = agree; and 5 =
strongly agree.
bMean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
Perceptions of Clinical Research Purposes and Procedures
Objective (lb) was to describe African Americans who were potential
participants in clinical research trials on their perception of clinical research purposes and
procedures. To measure the perception of clinical research purposes and procedures, an
eight item scale was used. The response scale utilized was a five-point Likert-type scale
with values ranging from I = “Strongly Disagree” to 5 = “Strongly Agree.” The middle
point (3) on the scale did allow the respondents the option of an “Unsure” answer. To
aid in the interpretation of this data, the researcher established an interpretive scale based
on the responses available to the study participants. This scale had descriptions and
corresponding values as follows: 1.00 to 1.50 = “Strongly Disagree,” 1.51 to 2.50 =
“Disagree,” 2.51 to 3.49 = “Unsure,” 3.50 to 4.49 = “Agree,” and 4.50 to 5.00 =
“Strongly Agree.”
When the data from the responses to the eight items on the scale were examined,
the statement with which the participants most strongly agreed was, “Participation in a
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clinical trial can help future generations’*(mean = 4.46, SD = .65). This statement was
classified using the interpretive scale as “Agree.” The statement with which participants
least agreed was, “Participation in a clinical trial can delay a disease” (mean = 3.19, SD =
1.15). The mean response to this statement was classified in the “Unsure” category.
Overall, six items were classified as “Agree,” and two items were classified as “Unsure.”
Table 4
Perception of Clinical Research Trial Purposes and Procedures of Potential African
American Participants
Item

n

Mean8

SD

Classificationb

Participation in a
clinical trial can help
future generations.

386

4.46

.65

Agree

Clinical trials are a
necessary way to learn
about treatments.

385c

4.39

.77

Agree

The information in the
consent form is impor
tant to help volunteers
decide about participa
tion in a clinical trial.

386

4.26

.81

Agree

It is important for
people to take part in
clinical trials.

386

4.24

.84

Agree

Participation in a clini
cal trial can help me and
my family.

386

4.21

.80

Agree

Blood work is
necessary in a clinical
trial.

386

4.10

.93

Agree

(Table continues)
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Participation in a clini
cal trial can prevent a
disease.

386

3.24

1.17

Unsure

t>
tn
oo

Participation in a clini
3.19
1.15
Unsure
cal trial can delay a
disease.
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly
agree.
"Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 —agree; 4.50-5.00 = strongly agree.
cOne respondent did not answer this item.
To further summarize the information regarding level of perception of clinical
research purposes and procedures, the researcher used factor analysis to determine if
underlying constructs could be identified in the scale. The analysis procedure used was
principal component analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum
number of factors to be extracted from the scale. Using a combination of the latent root
criterion, and the scree test criterion, the number o f factors to be extracted was deter
mined to be two. The results of the factor analysis including the factor, it’s label based
on the content of the items included in the factor, the percentage of variance explained
by each factor, and factor loadings for each o f the statements in each of the factors is
presented in Table 5. The two sub-scales were labeled by the researcher as “Participa
tion Benefits,” and “Prevention.” The first factor identified in the scale related to per
ceived benefits as a result of participation in clinical research trials. Items in this factor
included, “Participation in a clinical trial can help future generations,” “Participation in a
clinical trial can help me and my family”, “It is important for people to take part in clini-
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cal trials”, “Clinical trials are a necessary way to learn about treatments,” “The informa
tion in the consent form is important to help volunteers decide about participation in a
clinical trial”, and “Blood work is necessary in a clinical trial.” The factor loadings
ranged from a high of .83 to a low of .54 and explained 41.4 percent of the overall
variance in the scale.
The second factor explained an additional 23.6 percent of the overall scale vari
ance and included items related to prevention as a result of participation in clinical
research trials. Items in this factor included, “Participation in a clinical trial can delay a
disease”, and “Participation in a clinical trial can prevent a disease.” The factor loadings
ranged from a high of .93 to .91.
Table 5
Factor Analysis of Perception of Clinical Research Trial Purposes and Procedures of
Potential African American Participants
Factor 1

Factor 2

Participation in a clinical
trial can help future
genera-tions.

.83

.10

Participation in a clinical
trial can help me and my
family.

.79

.26

It is important for people
to take part in clinical
trials.

.79

.07

Factor-Participation
Benefits
(41.4% of variance
explained)

(Table continues)
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Clinical trials are a neces
sary way to learn about
treatments.

.77

.06

The information in the
consent form is important
to help volunteers decide
about participation in a
clinical trial.

.67

.08

Blood work is necessary in
a clinical trial.

.54

.31

Factor 1

Factor 2

Participation in a clinical
trial can delay a disease.

.11

.93

Participation in a clinical
trial can prevent a disease.

.15

.91

Factor- Prevention
(23.6% of variance
explained)

After the two sub-scales and items to be included in each were identified, the
researcher computed scale scores for each o f the two identified sub-scales. These sub
scale scores were identified as the mean of the items included in each of the respective
factors. For the first scale labeled “Participation Benefits,” the individual subject mean
scores ranged from a low of 4.09 to a high of 4.46 with an overall mean of 4.28, (SD =
.60). Using the interpretive scale, this scale received an overall rating classified as
“Agree.” The second scale was “Prevention,” and had individual subject means that
ranged from 3.19 to 3.24. The overall mean score was 3.22 (SD - 1.09) which was
classified in the “Unsure” category. When the sub-scale scores were examined, the
factor which received the highest mean score was the “Participation Benefits” sub-scale
(mean = 4.28, SD = .60) (see Table 6).
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Table 6
Perception o f Clinical Research Trial Purposes and Procedures Sub-Scale Scores of
Potential A f r ic a n American Participants
Sub-Scale

Items

Mean®

SD

Classification11

Range

Participation
Benefits

6

4.28

.60

Agree

4.09-4.46

3.19-3.24
1.09
2
3.22
Unsure
Prevention
‘Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure; 4 = agree; and 5 =
strongly agree.
bMean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
Advantages for the Individual of Participation in Clinical Research Trials
Objective (lc)was to describe African Americans who were potential participants
in clinical research trials on perceived advantages for the individual of participation in
clinical research trials. To measure the perceived advantages for the individual of
participation in clinical research trials, an eight item scale was used. The response scale
utilized was a five-point Likert-type scale with values ranging from 1 = “Strongly Dis
agree” to 5 = “Strongly Agree.” The middle point (3) on the scale did allow the respon
dents the option of an “Unsure” answer. To aid in the interpretation of this data, the
researcher established an interpretive scale based on the responses available to the study
participants. This scale had descriptions and corresponding values as follows: 1.00 to
1.50 = “Strongly Disagree;” 1.51 to 2.50 = “Disagree;” 2.51 to 3.49 = “Unsure;” 3.50 to
4.49 = “Agree;” and 4.50 to 5.00 = “Strongly Agree.”
When the data from the responses to the eight items on the scale were examined,
the statement with which the participants most strongly agreed was, “Doing something
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that will help others” (mean = 4.42, SD = .61). This statement was classified using the
interpretive scale as “Agree.” The statement with which participants least agreed was,
“Getting free medications” (mean = 3.53, SD = 1.04). The mean response to this state
ment was classified in the “Agree” category. Overall, all eight items were classified in
the “Agree” category as shown in Table 7.
Table 7

n

Mean*

SD

Classification6

Doing something that
will help others.

386

4.42

.61

Agree

Doing something
positive for self.

383e

4.21

.82

Agree

Getting better care and
follow-up (for example,
with laboratory tests).

383c

4.20

.83

Agree

Receiving the newest
treatment.

00

Perceived Advantages o f Participation in Clinical Research Trials of Potential African

3.93

.86

Agree

Helping to prevent a
disease.

385“

3.73

1.00

Agree

Getting a cash stipend.

384f

3.73

1.01

Agree

Helping to delay a
disease.

386

3.55

1.03

Agree

Item

1.04
384f
Agree
Getting free medication.
3.53
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly
agree.
‘’Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
Three respondents did not answer this item.
dFour respondents did not answer this item.
“One respondent did not answer this item.
Two respondents did not answer this item.
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To further summarize the information regarding perceived advantages for the
individual of participation in clinical research trials, the researcher used factor analysis to
determine if underlying constructs could be identified in the scale. The analysis
procedure used was principal components analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum
number of factors to be extracted from the scale. Using a combination of the latent root
criterion, the a ' priori criterion, and the scree test criterion, the number of factors to be
extracted was determined to be one. The results of the factor analysis including the fac
tor, it’s label based on the content of the items included in the factor, the percentage of
varianceexplained by each factor, and factor loadings for each of the items in the factor
is presented in Table 8. Since only one factor was extracted, the varimax rotation
method was not applicable. The sub-scale was labeled by the researcher as “Primary
Benefits.” The only factor identified in the scale related to the primary benefits of
participation in clinical research trials. Items in this factor included, “Getting better care
and follow-up (for example, with laboratory tests)”, “Doing something positive for self,”
“Receiving the newest treatment”, “Doing something that will help others”, “Helping to
delay a disease”, “Helping to prevent a disease”, “Getting free medications”, and
“Getting a cash stipend.” The factor loadings ranged from a high of .79 to a low of .58
and explained 47.4 percent of the overall variance in the scale (see Table 8).
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Table 8
F actor Analysis o f Perceived Advantages of Participation in Clinical Research Trials of

Potential African American Participants
Factor

Factor- Primary Benefits
(explained 47.4% of variance)
Getting better care and follow-up (for
example, with laboratory tests).

.79

Doing something positive for self.

.77

Receiving the newest treatment.

.70

Doing something that will help others.

.70

Helping to delay a disease.

.68

Helping to prevent a disease.

.65

Getting free medications.

.60

Getting a cash stipend.

.58

Since all the items loaded on one factor, the researcher computed an advantage
scale score labeled as “Primary Benefits.” This scale score was identified as the mean of
the items included in the factor. The “Primary Benefits” scale had individual subject
mean scores that ranged from a low of 3.53 to a high of 4.43 with an overall mean of
3.91 (SD = .61). Using the interpretive scale, this scale received an overall rating classi
fied as “Agree.
In addition to the eight specified advantages, respondents were provided the
opportunity to indicate an “Other” perceived advantage. If they did so, they were also
asked to specify what this “Other” advantage was. The respondents’ overall list of
“Other” advantages to participation in clinical research trials were combined into the
categories: participants (see Appendix D, question 24) and nonparticipants (see Appen-
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(fix E, question 24). There were nine respondents in the participant category that
specified “Leam about medicine and body,” and three specified “Meeting others” as
other advantages to participation in clinical trials. In addition, there were eleven
respondents in the nonparticipant category that specified “Knowledge obtained is
beneficial”, and five specified “If a clinical trial helps find a cure for a particular disease”
as other advantages to participation in clinical trials.
Disadvantages for the Individual o f Participation in Clinical Research Trials
Objective (Ic, Part II) was to describe African Americans who were potential
participants in clinical research trials on perceived disadvantages for the individual of
participation in clinical research trials. To measure the perceived disadvantages for the
individual of participation in clinical research trials, a six item scale was used. The
response scale utilized was a five-point Likert-type scale with values ranging from 1 =
“Strongly Disagree” to 5 = “Strongly Agree.” The middle point (3) on the scale did
allow the respondents the option of an “Unsure” answer. To aid in the interpretation of
this data, the researcher established an interpretive scale based on the responses available
to the study participants. This scale had descriptions and corresponding values as
follows: 1.00 to 1.50 = “Strongly Disagree;” 1.51 to 2.50 = “Disagree;” 2.51 to 3.49 =
“Unsure;” 3.50 to 4.49 = “Agree;” and 4.50 to 5.00 = “Strongly Agree.”
When the data from the responses to the six items on the scale were examined,
the statement with which the participants most strongly agreed was, “Experiencing side
effects of the treatment” (mean = 3.26, SD = 1.10). This statement was classified using
the interpretive scale as “Unsure.” The statement with which participants least agreed
was, “Being treated like a “guinea pig” (mean = 2.71, SD = 1.25). The mean response
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to this statement was classified in the “Unsure” category. Overall, all six items were
classified in the “Unsure” category (see Table 9).
Table 9
Perceived Disadvantages of Participation in Clinical Research Trials of Potential African
American Participants
n

Mean*

SD

Classificationb

Experiencing side effects of
the treatment.

384c

3.26

1.10

Unsure

Disrupting one’s normal
daily routine.

379d

3.15

1.19

Unsure

2.99

1.27

Unsure

Having to miss work.

100
*>

Item

Having to arrange childcare.

373r

2.89

1.26

Unsure

Losing one’s privacy.

oo
fO

2.72

1.16

Unsure

384c
2.71
1.25
Unsure
Being treated like a “guinea
«
pig.
“Response scale: I = strongly disagree; 2 - disagree; 3 = unsure, 4 = agree; 5 = strongly
agree.
bMean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
T w o respondents did not answer this item.
dSeven respondents did not answer this item.
“Four respondents did not answer this item.
Thirteen respondents did not answer this item.
_ *

To further summarize the information regarding perceived disadvantages for the
individual o f participation in clinical research trials, the researcher used factor analysis to
determine if underlying constructs could be identified in the scale. The analysis
procedure used was principal components analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum
number of factors to be extracted from the scale. Using a combination o f the latent root
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criterion, the a ' priori criterion, and the scree test criterion, the number of factors to be
extracted was determined to be one. The results of the factor analysis including the fac
tor, it’s label based on the content of the items included in the factor, the percentage of
variance explained by the factor, and factor loadings for each of the items in the factor is
presented in Table 10. Since only one factor was extracted, the varimax rotation method
was not applicable. The sub-scale was labeled by the researcher as “Drawbacks.” The
only factor identified in the scale related to circumstances that would hinder participation
in clinical research trials. Items in this factor included, “Having to miss work”, “Disrupt
ing one’s normal daily routine”, “Having to arrange childcare,” “Experiencing side
effects o f the treatment”, “Losing one’s privacy”, and “Being treated like a “guinea pig.”
The factor loadings ranged from a high of .80 to a low of .69 and explained 58.2 percent
o f the overall variance in the scale (see Table 10).
Table 10
Factor Analysis of Perceived Disadvantages of Participation in Clinical Research Trials
o f Potential African American Participants
Factor

Factor- Drawbacks
(explained 58.2% of variance)
Having to miss work.

.80

Disrupting one’s normal daily routine.

.80

Having to arrange childcare.

.77

Experiencing side effects of the
treatment.

.76

Losing one’s privacy.

.75

Being treated like a “guinea pig.”

.69
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Since all the items loaded on one factor, the researcher computed a disadvantage
scale score. This scale score was identified as the mean of the items included in the
factor. The disadvantage scale was labeled by the researcher as “Drawbacks.” This scale
had individual subject mean scores that ranged from a low of 2.69 to a high of 3.25 with
an overall mean of 2.95 (SD = .92). Using the interpretive scale, this scale received an
overall rating classified as “Unsure.”
In addition to the six specified disadvantages, respondents were provided the
opportunity to indicate an “Other” perceived disadvantage. If they did so, they were also
asked to specify what this “Other” disadvantage was. The respondents overall list of
“Other9' disadvantages to participation in clinical research trials were combined into the
categories: participants (see Appendix D, question 31) and nonparticipants (see Appen
dix E, question 31). There were ten respondents in the participant category that speci
fied “Dates and times can't be changed or rescheduled, inconvenient,” five specified
“Forcing someone to overeat to maintain a specific weight; many studies are too long”
and, four individuals specified “Trip to clinic” as other disadvantages for the individual of
participation in clinical research trials. In addition, eleven nonparticipants specified
“Risk to your health,” seven specified “Getting to clinic,” four specified ‘Time consum
ing; inconvenient,” three specified “Overcoming past atrocities where African Americans
were deliberately infected (i.e. syphilis virus),” and, three specified “Not knowing if you
are receiving treatment or sugar pill” as other disadvantages for the individual o f partici
pation in clinical research trials.
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Characteristics o f Current and Past Participation in Clinical Research Trials
Objective one (d) was to describe African Americans who were potential partici
pants in clinical research trials on characteristics of current and past participation in
clinical research trials. Respondents were asked a series of six questions that were
designed to accomplish this part of the descriptive objective. First, they were asked if
they had ever been asked to participate in a clinical trial. More than half (n = 213,
55.3%) indicated that they had been asked to participate in a clinical trial (see Table 11).
In addition, study participants were asked if they had previously participated in a clinical
trial. Slightly more than a third of the participants (n = 145,37.7%) indicated a response
of “Yes” to this question. However, when asked if they were currently participating in a
clinical trial, a total of 64 (16.7%) indicated that they were currently enrolled in a clinical
research trial (see Table 11).
Those individuals who responded “No” to all three of the initial items asked
above were asked if they would participate in clinical research trials in the future if they
were invited to do so. O f the eligible respondents to this item, 111 (90.2%) indicated
that they would participate in the future if they were asked (see Table 11).
Participants were also asked to report whether or not they had ever decided to
decline participation in a clinical trial after they had been classified as eligible to be a
research participant The majority of the participants (n = 288,78.3%) indicated a “No”
response to this question. Respondents were provided a list of possible reasons for
choosing not to participate in the research activity and were asked to identify the primary
reason for their negative decision. The reason that was identified most often was,
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Table 11
Clinical R esearch Trial Current and Past Participation Status o f A frican A m ericans

No

Yes

Item

Total

n

%

n

%

n

%

Have you ever
been asked to
participate in a
clinical trial?

213

55.3

172

44.7

385*

100

Have you previous
ly participated in a
clinical trial?

145

37.7

240

62.3

385“

100

Are you currently
enrolled in a clini
cal trial?

64

16.7

320

83.3

384b

100

If you were asked
to participate in a
clinical trial in the
future, would you
participate?

111

90.2

12

9.8

123°

100

21.7
288
80
Have you ever
decided not to
participate in a
clinical trial after
being eligible?
“One respondent did not answer this item.
'Two respondents did not answer this item.
T his item was not applicable for 263 respondents.
''Eighteen respondents did not answer this item.

78.3

368"

100

“Changed jobs, schedule would not permit” (n = 20,26.3%). Each of two other reasons
were identified by 12 (15.8%) of the study participants. These reasons were, “Changed
mind, due to fear” and “Live too far from the research center” (see Table 12). Seventeen
o f the respondents indicated that some “Other” reason was their primary reason for
choosing not to participate. These individuals were also asked to specify what that
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“Other” reason was. Some of the “Other” primary reasons for choosing not to partici
pate was, “Busy schedule,” and “Hours of participation were during work hours” (see
Appendices D and E for a complete list).
Table 12
Primary Reason Cited for Not Participating bv African Americans Who Were Eligible
But Chose Not to Participate in Clinical Research Trials
Item

n

%

Changed jobs, schedule
would not permit.

20

26.3

Changed mind, due to fear.

12

15.8

Live too far from research
center.

12

15.8

Too much effort involved.

8

10.5

Too many lab tests
required.

6

7.9

Work too far from
research center.

1

1.3

Other* (please specify)

17

22.4

76b
100
Total
*A complete listing of other reasons reported by respondents is presented in Appendices
D andE.
'Tour respondents did not answer this item.
Exposure to Selected Experiences Which are Preliminary to Participation in Clinical
Research Trials
Objective one (e) was to describe African Americans who were potential partici
pants in clinical research trials based on exposure to selected experiences which are pre
liminary to participation in clinical research trials. Respondents were asked a series of
four questions that were designed to accomplish this part of the descriptive objective.
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First, they were asked if they received any verbal or written materials that described what
the clinical trial was about and what they would need to do. More than half (n = 242,
66.5%) indicated that they did receive verbal or written materials that described what the
clinical trial was about and what they would need to do (see Table 13). Second, study
participants were asked if they talked to family or friends before making their decision to
participate or not participate in a clinical research trial. More than half (n = 217,59.6%)
indicated that they did not talk to family or friends before making their decision to parti
cipate or not participate in a clinical research trial (see Table 13). Third, study partici
pants were asked if they talked to their doctor before making their decision to participate
or not participate in a clinical research trial. Two hundred ninety eight (81.6%) of study
participants did not talk with their doctor before making their decision to participate or
not participate in a clinical research trial (see Table 13). Finally, study participants were
asked if they had a family history of the disease being researched that prompted their
decision to participate or not participate in a clinical research trial. Slightly more than
half (n = 184,51.1%) indicated that they did not have a family history of the disease
being researched that prompted their decision to participate or not participate in a
clinical research trial as shown in Table 13.
In addition to the four specified exposures to selected experiences which are pre
liminary to participation in clinical research trials, respondents were provided the oppor
tunity to indicate an “Other” exposure to selected experiences which are preliminary to
participation in clinical research trials. The respondents overall list of other selected
experiences were combined into the categories: participants (see Appendix D, question
42) and nonparticipants (see Appendix E, question 42). The responses varied for exam51

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 13
Exposure to Selected Experiences bv Potential A frican Americans Which are Prelim inary
to Participation in Clinical Research Trials
Item

Yes

No

Unsure

Total

n

%

n

%

n

%

n

%

Did you receive any verbal
or written materials that
described what the clinical
trial was about?

242

66.5

98

26.9

24

6.6

364*

100

Did you talk to family or
friends before making your
decision?

133

36.5

217

59.6

14

3.8

364“

100

Did you talk to your
doctor before making your
decision?

55

15.1

298

81.6

12

3.3

365b

100

149 41.4 184 51.1
Did you have a family
history o f the disease being
researched?
“Twenty two respondents did not answer this item.
‘Twenty one respondents did not answer this item.
Twenty six respondents did not answer this item.

27

7.5

360c

100

pie, the participant category had 17 respondents that specified “Having family history of
disease,” while 12 in the nonparticipant category specified “Never asked to participate”
and another 12 nonparticipants specified “Did not fit profile,” as other exposures to
selected experiences which are preliminary to participation in clinical research trials.
Perceptions Regarding the Need for Selected Changes in Preparation for Participation in
Clinical R esearch Trials
Objective one (f) was to describe African Americans who were potential partici
pants in clinical research trials on their perception regarding the need for selected
changes in preparation for participation in clinical research trials. To measure
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perceptions regarding the need for selected changes in preparation for participation by
African Americans in clinical research trials, a six item scale was used. The response
scale utilized was a five-point Likert-type scale with values ranging from 1 = “Strongly
Disagree” to 5 = “Strongly Agree.” The middle point (3) on the scale did allow the
respondents the option of an “Unsure” answer. To aid in the interpretation of this data,
the researcher established an interpretive scale based on the responses available to the
study participants. This scale had descriptions and corresponding values as follows: 1.00
to 1.50 = “Strongly Disagree;” 1.51 to 2.50 = “Disagree;” 2.51 to 3.49 = “Unsure;” 3.50
to 4.49 = “Agree;” and 4.50 to 5.00 = “Strongly Agree.”
When the data from the responses to the six items on the scale were examined,
the statement with which the participants most strongly agreed was, “Hearing about the
good things that have been discovered from clinical trials” (mean = 4.37, SD = .76).
This statement was classified using the interpretive scale as “Agree.” The statement with
which participants least agreed was, “Informational meeting about the clinical trial,
presented by the nurse” (mean = 3.91, SD = .97). The mean response to this statement
was classified in the “Agree” category (see Table 14).
To further summarize the perceptions regarding the need for selected changes in
preparation for participation in clinical research trials, the researcher used factor analysis
to determine if underlying constructs could be identified in the scale. The analysis proce
dure used was principal components analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum
number of factors to be extracted from the scale. Using a combination of the latent root
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Table 14
Perceptions Regarding the Need for Selected Changes in Preparation for Participation of
Potential African Americans in Clinical Research Trials
Item

n

Mean1

SD

Classification15

381c

4.37

.76

Agree

Informational meeting about the
clinical trial presented by the
physician.

382“

4.27

.83

Agree

.93

Agree

4.18

TV shows or videotapes with
African Americans in clinical
trials.

380e

4.00

1.01

Agree

Informational meeting about the
clinical trial presented by
African Americans.

381c

3.98

.99

Agree

Talking to other African
Americans who have taken part
in clinical trials.

OO

o

Hearing*about the good things
that have been discovered from
clinical trials.

o

00

.97
3.91
Agree
Informational meeting about the
clinical trial presented by the
nurse.
“Response scale: 1 = strongly disagree; 2 - disagree; 3 = unsure, 4 = agree; 5 = strongly
agree.
'’Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
Tive respondents did not answer this item.
‘‘Four respondents did not answer this item.
cSix respondents did not answer this item.
criterion, the a ' priori criterion, and the scree test criterion, the number of factors to be
extracted was determined to be one. The results of the factor analysis including the fac-
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tor, it’s label based on the content o f the items included in the factor, the percentage of
variance explained by the factor, and factor loadings for each of the items in the factor
is presented in Table 15. Since only one factor was extracted, the varimax rotation
method was not applicable. The sub-scale was labeled by the researcher as “Ideas/
Suggestions.” The only factor identified in the scale related to ideas/suggestions for
ways to help people learn more about clinical research trials. Items in this factor includ
ed, “Informational meeting about the clinical trial presented by African Americans,” “TV
shows or videotapes with African Americans in clinical trials”, “Talking to other African
Americans who have taken part in clinical trials”, “Hearing about the good things that
have been discovered from clinical trials”, “Informational meeting about the clinical trial
presented by the physician”, and “Informational meeting about the clinical trial presented
by the nurse.” The factor loadings ranged from a high of .79 to a low of .64 and
explained 55.1 percent of the overall variance in the scale (see Table 15).
Table 15

Factor Analysis of Perceptions Regarding the Need for Selected Changes in Preparation
for Participation of Potential African Americans in Clinical Research Trials
Factor- Ideas/Suggestions
(explained 55.1% of variance)

Factor

Informational meeting about the clinical
trial, presented by African Americans.

.79

TV shows or videotapes with African
Americans in clinical trials.

.78

Talking to other African Americans who
have taken part in clinical trials.

.78
(Table continues)
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Hearing about the good things that have
been discovered from clinical trials.

.73

Informational meeting about the clinical
trial, presented by the physician.

.72

Informational meeting about the clinical
trial, presented by the nurse.

.64

Since all the items loaded on one factor, the researcher computed an ideas/
suggestion scale score. This scale score was identified as the mean of the items included
in the factor. The “Ideas/Suggestions” scale had individual subject mean scores that
ranged from a low of 3.92 to a high of 4.37 with an overall mean of 4.12 (SD = .68).
Using the interpretive scale, this scale received an overall rating classified as “Agree.”
In addition to the six specified perceptions regarding the need for selected
changes in preparation for participation in clinical research trials, respondents were
provided the opportunity to indicate an “Other” perceptions regarding the need for
selected changes in preparation for participation in clinical research trials. The respon
dents overall list of other perceptions regarding the need for selected changes in prepara
tion for participation in clinical research trials were combined into the categories:
participants (see Appendix D, question 49) and nonparticipants (see Appendix E,
question 49). The responses varied for example, nine respondents in the participant
group specified “More advertising in African American periodicals, TV commercials
with African Americans, post newsletters in African American communities.” There were
six respondents in the nonparticipant category that specified “Research about the test not
just from African Americans but whomever has participated.”
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Demographic Characteristics

Objective one (g) was to describe African Americans who were potential partici
pants in clinical research trials on selected personal demographic characteristics.
Respondents were asked to provide personal background information in the following
areas: (1) gender, (2) age, (3) marital status, (4) education level, (5) employment status,
(6) household income, (7) distance from research center, and (8) overall health status.
•

Gender. The largest group (n = 308,79.8%) of respondents were female
and 20.2% (n = 78) were male.

•

Age. Respondents were given several age groups and asked to select the
category that represented their age. The largest age group (n = 133,
34.5%) of respondents selected the 46-55 year group. The second largest
age group (n = 107,27.8%) of respondents was the 36-45 years group.
The remaining age groups are shown in Table 16.

Table 16
Age Group of Potential African American Participants in a Clinical Research Trial
Item

n

%

< 18 years

1

.3

18-25 yrs.

23

6.0

26-35 yrs.

55

14.3

36-45 yrs.

107

27.8

46-55 yrs.

133

34.5

56-65 yrs.

51

13.2

66 yrs. and over

15

3.9
(Table continues)
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Total
385*
•One respondent did not answer this item.
•

100.0

Marital Status. Respondents were asked to choose whether they were
married, divorced/separated, never married or widowed. The largest
group (n = 192,49.9%) of respondents indicated they were married. The
second largest group (n = 98,25.5%) o f respondents were
divorced/separated. Responses for all categories of marital status are
shown in Table 17.

Table 17
Marital Status of Potential African American Participants in a Clinical Trial
Item

n

%

Married

192

49.9

Divorced/Separated

98

25.4

Never married

70

18.2

Widowed

25

6.5

Total
385*
•One respondent did not answer this item.
•

100.0

Education. Respondents were given a list of education levels and asked
to select the highest education level they had completed. The largest
group (n = 151,39.3%) of respondents indicated that they had completed
1-3 years of college/business or technical school. The second largest
group (n = 82,21.4%) of respondents had a college degree. The third
largest group (n = 67,17.5%) o f respondents had post graduate degrees.
The respondents* education levels are shown in Table 18.
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Table 18
Education Level of Potential African American Participants in a Clinical Research Trial
Item

n

%

Grades 0-8

4

1.0

Some High School (HS)

27

7.0

HS diploma/GED

53

13.8

1-3 yrs.
college/business/technical

151

39.3

College degree

82

21.4

Post graduate degree

67

17.5

384i
Total
“Two respondents did not answer this item.
•

100.0

Employment status. Respondents were asked to indicate their present
employment status. The largest group (n = 271,70.4%) of respondents
indicated they were employed full time. The employment status for all
respondents is shown in Table 19.

Table 19
Employment Status of Potential African American Participants in Clinical Research
Trials
Item

n

%

Fulltime

271

70.4

Unemployed

33

8.6

Retired

32

8.3

Part time

31

8.0

Medical disability

18

4.7
(Table continues)
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"One respondent did not answer this item.
•

Household income. Respondents were asked to indicate their
approximate household income. The largest group (n = 76,20.5%) of
respondents indicated a house- hold income in the $20,000 - $29,999
range. The second largest group (n = 67,18.1%) of respondents
indicated a household income of $70,000 and up. The third largest group
(n = 62,16.7%) of respondents indicated a household income of $10,000
- $19,999 per year. Household income of respondents is presented in
Table 20.

Table 20
Household Income of Potential African American Participants in a Clinical Research
Trial
Item

n

%

<$10,000 per year

52

14.0

$10,000-$19,999

62

16.7

$20,000 - $29,999

76

20.5

$30,000 - $39,999

42

11.3

$40,000 - $49,999

30

8.1

$50,000 - $59,999

42

11.3

$70,000 and above

67

18.1

Total
371"
"Fifteen respondents did not answer this item.
•

100.0

Distance from Respondents Domicile to Research Center. Respondents
were asked to indicate the approximate distance from their domicile to
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the research center from a list of specified distances. The largest group (n
= 115,30.4%) of respondents indicated that they lived within 15 miles of
the research center. One hundred two (27.0%) of respondents indicated
that they lived within 7 miles of the research center (see Table 21).
Table 21
Distance to the Research Center from Domicile Reported bv Potential African American
Participants in a Clinical Research Trial
Item

n

%

Within 3 miles

57

15.0

Within 7 miles

102

27.0

Within 15 miles

115

30.4

Within 20 miles

52

13.8

More than 20 miles

52

13.8

00

Total
‘Eight respondents did not answer this item.

100.0

Distance from Respondents Worksite to the Research Center.
Respondents were also asked to report the approximate distance from
their worksite to the research center. The largest group (n = 99,30.2%)
o f respondents indicated that their worksite was within 7 miles o f the
research center. The second largest group (n = 78,23.8%) of
respondents indicated that they worked within 15 miles of the research
center. The third largest group (n = 61,18.6%) o f respondents indicated
that they worked with 3 miles of the research center (see Table 22).
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Table 22
Distance to the Research Center from Worksite Reported bv Potential African American
Participants in a Clinical Research Trial
Item

n

%

At Research Center

13

4.0

Within 3 miles

61

18.6

Within 7 miles

99

30.2

Within 15 miles

78

23.8

Within 20 miles

35

10.6

More than 20 miles

42

12.8

Total
328“
“Fifty eight respondents did not answer this item.

100.0

Overall Health Status. Respondents were asked to indicate the item that
best described their current health status. The largest group (n = 152,
39.5%) of respondents indicated that they were in “Good” health. The
second largest group (n = 126,32.7%) of respondents indicated they
were in “Very Good” health. The health status of respondents is shown
in Table 23.
Table 23
Overall Health Status of Potential African American Participants in a Clinical Research
Trial
Item

n

%

Good

152

39.5

Very Good

126

32.7

Excellent

65

16.9
(Table continues)
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Fair

36

9.4

Poor

6

1.6

385“
Total
"One respondent did not answer this item.

100.0

Objective Two
Objective two (a) of the study was to describe and compare African Americans
who have participated in clinical research trials and those who have not participated in
clinical research trials on selected perceptual and demographic measures. The first of
these measures was knowledge of clinical research processes. The first step in this pro
cess was to describe the research respondents on their knowledge of clinical research
trials. As identified previously, knowledge was measured using seven items to which
respondents were asked to respond using a five point Likert-type scale. The item with
which the participant group most strongly agreed was “Volunteers can refuse to partici
pate in a clinical trial” (Mean = 4.73) (see Table 24). The item with which participants
were found to exhibit the lowest level of agreement was “Volunteers are made aware of
any possible complications or side effects of taking part in a clinical trial” (Mean = 4.17).
The nonparticipants in the study reported the highest level of agreement with the same
item as the participant group. This item was “Volunteers can refuse to participate in a
clinical trial” (Mean = 4.52). However, the item with which nonparticipants expressed
the lowest level o f agreement was “Volunteers usually receive a cash stipend for
participation in a clinical trial” with a mean rating of 3.81 (see Table 24).
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Table 24
Level of Knowledge of Clinical Research Trials Among African Americans bv Participa
tion Status
Item

Participants

Nonparticipants

Mean*

SD

Mean*

SD

Volunteers can refuse to
participate in a clinical
trial.

4.73

.48

4.52

.76

Clinical trials are needed to
study the effects of
treatments.

4.50

.64

4.44

.70

Volunteers can change
their mind at any time and
withdraw from a clinical
trial.

4.46

.83

4.02

1.03

Volunteers receive infor
mation needed to decide
whether they want to take
part in a clinical trial.

4.45

.73

3.86

1.14

Volunteers usually receive
a cash stipend for partici
pation in a clinical trial.

4.28

.78

3.81

.90

Volunteers are told about
the possible risks and
benefits o f taking part in a
clinical trial.

4.20

.91

4.00

1.01

3.91
1.03
Volunteers are made
4.17
.95
aware of any possible
complications or side
effects of taking part in a
clinical trial.
“Response scale: 1 = strongly disagree; 2 = cisagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
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To accomplish the second aspect o f this objective, the researcher needed to com
pare the participants and nonparticipants on their level of knowledge of clinical research
trials. However, to conduct individual statistical comparisons on each of the items used
in the knowledge scale would have created an unacceptably inflated alpha level due to
the inflation of experiment-wise error which occurs when related items are used in
multiple statistical comparisons. Therefore, to accomplish this task, the researcher
utilized the underlying constructs and the corresponding sub-scale scores derived from
the factor analysis in objective one of the study.
When these two sub-scale scores were compared by participation status of the
study respondents using the independent samples t-test procedure, the results showed
that the two groups were significantly different on both of the sub-scale scores. On the
first knowledge factor which was labeled by the researcher as “Information Provided,”
the participant group had a mean score of 4.28 (SD = .63) and the nonparticipant group
had a mean score of 3.90 (SD = .81) (t 3g4= 4.943, p < .001). This indicated that the
participant group reported significantly higher levels of agreement with items in the
“Information Provided” knowledge factor than did the nonparticipants.
For the second knowledge factor, labeled as “Awareness” by the researcher, simi
lar results were found (t 3g4 = 4.093, p < .001). With the mean values for the groups
identified as 4.57 (SD = .48) for the participant group and 4.32 (SD = .63) for the non
participant group, these results also indicated that the participants had a significantly
higher level of agreement with the items in the “Awareness” knowledge factor than did
the nonparticipants.
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Objective two (b) of the study was to describe and compare African Americans
who have participated in clinical research trials and those who have not participated in
clinical research trials on their perceptions of clinical research purposes and procedures.
The first step in objective two (b) was to describe the research respondents on their
perceptions of clinical research purposes and procedures. As identified previously,
perceptions were measured using eight items to which respondents were asked to
respond using a five point Likert-type scale. The item with which the participant group
most strongly agreed was “Participation in a clinical trial can help future generations”
(Mean = 4.59) (see Table 25). The item with which participants were found to exhibit
the lowest level of agreement with was “Participation in a clinical trial can prevent a
disease” (Mean = 3.35). The item with which the nonparticipants most strongly agreed
was “Clinical trials are a necessary way to learn about treatments” (Mean = 4.39) (see
Table 25). The item with which the nonparticipants expressed the lowest level of
agreement was “Participation in a clinical trial can delay a disease” (Mean = 3.07).
Table 25
Perceptions of Clinical Research Trials Among African Americans bv Participation
Status
Item

Participants

Nonparticipants

Mean1

SD

Mean1

SD

Participation in a clinical
trial can help future
generations.

4.59

.55

4.37

.70

Participation in a clinical
trial can help me and my
family.

439

.70

4.09

.85

(Table continues)
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Clinical trials are a neces
sary way to learn about
treatments.

4.39

.76

4.39

.77

The information in the
consent form is important
to help volunteers decide
about participation in a
clinical trial.

4.37

.75

4.18

.84

It is important for people
to take part in clinical
trials.

4.32

.79

4.18

.86

Blood work is necessary in
a clinical trial.

4.30

.84

3.96

.97

Participation in a clinical
trial can delay a disease.

3.37

1.11

3.07

1.16

Participation in a clinical
3.35
1.13
3.16
1.20
trial can prevent a disease.
•Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
To accomplish the second aspect of objective two (b), the researcher needed to
compare the participants and nonparticipants on their perceptions of clinical research
purposes and procedures. However, to conduct individual statistical comparisons on
each of the items used in the perception scale would have created an unacceptably
inflated alpha level due to the inflation of experiment-wise error. Therefore, to accomlish this task, the researcher utilized the underlying constructs and the corresponding
sub-scale scores derived from the factor analysis in objective one.
When these two sub-scale scores were compared by participation status of the
study respondents using the independent samples t-test procedure, the results showed
that the two groups were significantly different on both o f the sub-scale scores. On the
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first perception factor which was labeled by the researcher as “Participation Benefits,”
mean scores included for the participant group 4.39 (SD = .54) and for the nonpartici
pant group 4.19 (SD = .62)(t 3g4 = 3.249, j> = .001). This indicated that the participant
group reported significantly higher levels of agreement with items in the “Participation
Benefits” perception factor than did the nonparticipants.
For the second perception factor, labeled as “Prevention” by the researcher, simi
lar results were found (t 384 “ 2.241, £ = .026). With the mean values for the groups
identified for the participant group as 3.37 (SD - 1.07) and for the nonparticipant group
3.12 (SD = 1.09) these results also indicated that the participants had a significantly
higher level of agreement with the items in the “Prevention” perception factor than did
the nonparticipants.
Objective two (c) Part I was to describe and compare African Americans who
have participated in clinical research trials and those who have not participated in clinical
research trials on perceived advantages for the individual of participation in clinical
research trials. The first step in this process was to describe the research respondents on
their perceived advantages for the individual of participation in clinical research trials.
As identified previously, the perceived advantages were measured using eight items to
which respondents were asked to respond using a five point Likert-type scale. The item
with which the participant group most strongly agreed was “Doing something that will
help others” (Mean = 4.51) (see Table 26). The item with which participants were found
to exhibit the lowest level of agreement with was “Getting free medications” (Mean =
3.61). '‘The nonparticipants in the study reported the highest level of agreement with the
same item as the participant group. This hem was “Doing something that will help
68
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others” (Mean = 4.36). However, the item with which nonparticipants expressed the
lowest level of agreement was “Helping to delay a disease” with a mean rating of 3.46
(see Table 26).
Table 26
Perceived Arivantapes of Clinical Research Trials Among African A m ericans hv
Participation Status
Item

Nonparticipants

Participants
Mean*

SD

Mean*

SD

Doing something that will
help others.

4.51

.58

4.36

.62

Getting better care and
follow-up (for example,
with laboratory tests).

4.40

.79

4.06

.83

Doing something positive
for self.

4.38

.74

4.09

.86

Getting a cash stipend.

3.99

.97

3.54

.99

Receiving the newest
treatment.

3.88

.90

3.96

.83

Helping to prevent a
disease.

3.78

1.02

3.70

.98

Helping to delay a disease.

3.70

1.05

3.46

1.01

1.14
3.61
3.48
.97
Getting free medications.
'Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
To accomplish the second aspect of Part I of this objective, the researcher needed
to compare the participants and nonparticipants on their perceived advantages for the in
dividual of participation in clinical research trials. However, to conduct individual statis-
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tical comparisons oa each of the items used in the advantage scale would have created an
unacceptably inflated alpha level due to the inflation of experiment-wise error. Therefore,
to accomplish this task, the researcher utilized the underlying construct and the corre
sponding sub-scale score derived from the factor analysis conducted in objective one.
When this sub-scale score was compared by participation status o f the study
respondents using the independent samples t-test procedure, the results showed that the
two groups were significantly different. There was one advantage factor labeled by the
researcher as “Primary Benefits” with a mean score of 4.03 (SD = .60) for the participant
group and 3.83 (SD = .61) for the nonparticipant group (t 384 = 3.179, p = .002). This
indicates that the participant group reported significantly higher levels o f agreement with
items in the “Primary Benefits” advantage factor than did the nonparticipants.
Objective two (c) Part II was to describe and compare African Americans who
have participated in clinical research trials and those who have not participated in clinical
research trials on perceived disadvantages for the individual of participation in clinical
research trials. The first step in this process was to describe the research respondents on
their perceived disadvantages for the individual of participation in clinical research trials.
The perceived disadvantages were measured using six items to which respondents were
asked to respond using a five point Likert-type scale. The item with which the
participant group most strongly agreed was “Experiencing side effects of the treatment”
(Mean = 2.99) (see Table 27). The item with which participants were found to exhibit
the lowest level of agreement with was “Being treated like a “guinea pig” (Mean = 2.31).
The nonparticipants in the study reported the highest level of agreement with the same
hem as the participant group. This item was “Experiencing side effects o f the treatment”
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(Mean = 3.46). However, the item with which nonparticipants expressed the lowest
level o f agreement was “Losing one’s privacy” with a mean rating o f 2.94 (see Table
27).
Table 27
Perceived Disadvantages of Clinical Research Trials Among African Americans bv
Participation Status
Participants

Item

Nonparticipants

Mean*

SD

Mean*

SD

Experiencing side effects
o f the treatment.

2.99

1.08

3.46

1.07

Disrupting one’s normal
daily routine.

2.90

1.24

3.32

1.13

Having to miss work.

2.74

1.33

3.17

1.20

Having to arrange child
care.

2.58

1.28

3.11

1.20

Losing one’s privacy.

2.39

1.11

2.94

1.14

2.31
1.16
2.98
1.23
Being treated like a
“guinea pig.”
•Response scale: 1 = strongly disagree; 2 = cisagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
To accomplish the second aspect of Part II of this objective, the researcher
needed to compare the participants and nonparticipants on their perceived disadvantages
for the individual o f participation in clinical research trials. However, to conduct individ
ual statistical comparisons on each o f the items used in the disadvantage scale would
have created an unacceptably inflated alpha level due to the inflation of experiment-wise
error. Therefore, to accomplish this task, the researcher utilized the underlying construct
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and the corresponding sub-scale score derived from the factor analysis conducted in
objective one.
When this sub-scale score was compared by participation status of the study
respondents using the independent samples t-test procedure, the results showed that the
two groups were significantly different on their perceptions regarding disadvantages for
the individual of participation in clinical research trials. There was one disadvantage
factor labeled by the researcher as “Drawbacks” with a mean score of 2.65 (SD = .87)
for the participant group and 3.16 (SD = .90) for the nonparticipant group (t JM= -5.595,
g < .001). This indicates that the nonparticipant group reported significantly higher
levels of agreement with the items in the “Drawbacks” disadvantage factor than did the
participants.
Objective two (d) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials on characteristics of their current and past participation in clinical research
trials. A total of six aspects of clinical research participation status were examined as
part o f this objective. The first aspect was whether or not the respondents had ever been
asked to participate in a clinical trial. For the participant group, the majority (n = 126,
79.7%) of respondents indicated that they had been asked to participate in a clinical trial.
In contrast, the majority of nonparticipants (n= 140,61.7%) indicated that they had not
been asked to participate in a clinical trial (see Table 28).
The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they had ever been asked to participate in a clinical trial. This
was accomplished using the Chi-square test of independence to determine if the two
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Table 28
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not
African A m ericans Indicated That They Had Ever Been Asked to Participate
Have vou ever been asked to participate
in a clinical trial?

Participation Status
Participant

Nonparticipant

Yes

126
79.7%

87
38.3%

No

32
20.3%

140
61.7%

Total

158
100%

227
100%

Mote. X2(ij= 64.67, e < .001
variables (whether or not they had participated and whether or not they had ever been
asked to participate) were independent. The resulting calculated Chi-square value (x2, d
= 64.67, p < .001) indicated that the variables were not independent. The nature of the
association between the variables was such that a greater proportion of the participants
indicated that they had been asked to participate while a greater proportion of the
nonparticipants indicated they had not been asked to participate.
The second aspect of characteristics of current and past participation in clinical
research trials was, whether or not the respondents had previously participated in a
clinical trial. For the participant group, the majority (n = 114,72.2%) o f respondents
indicated that they had previously participated in a clinical trial. In contrast, the majority
o f nonparticipants (n = 196,86.3%) indicated that they had not previously participated in
a clinical trial (see Table 29).
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Table 29
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not
African Americans Indicated That They Had Previously Participated
Have you previously participated in a
clinical trial?

Participation Status
Participant

Nonparticipant

Yes

114
72.2%

31
13.7%

No

44
27.8%

196
86.3%

Total

158
100%

228
100%

Mote. x2,„= 135.77, B < . 001
The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they previously participated in a clinical trial. This was accom
plished using the Chi-square test of independence to determine if the two variables
(whether or not they participated and whether or not they had previously participated)
were independent. The resulting calculated Chi-square value (X2(i>= 135.77, g < .001)
indicates that the variables were not independent. The nature of the association between
the variables was such that a greater proportion of the participants (72.2%) indicated
that they previously participated while a greater proportion of the nonparticipants
(86.3%) indicated they had not previously participated.
The third aspect of characteristics o f current and past participation in clinical
research trials was, whether or not the respondents were currently enrolled in a clinical
trial. For the participant group, approximately one third (n = 53,33.5%) of respondents
indicated they were currently enrolled in a clinical trial. In contrast, fewer of the
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nonparticipants (n= 11,4.9%) indicated that they were not currently enrolled in a
clinical trial (see Table 30).
Table 30
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not
African Americans Indicated That They Were Currently Enrolled
Are vou currently enrolled in a clinical
trial?

Participation Status
Participant

Nonparticipant

Yes

53
33.5%

11
4.9%

No

105
66.5%

215
95.1%

Total

158
100%

226
100%

Note. x2(l)= 55.06.p < .001
The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they were currently enrolled in a clinical trial. This was
accomplished using the Chi-square test of independence to determine if the two variables
(whether or not they had participated and whether or not they were currently enrolled)
were independent. The resulting calculated Chi-square value (x2(I)= 55.06, g < .001) in
dicated that the variables were not independent. The nature o f the association between
the variables was such that a greater proportion of the participants (33.5%) indicated
that they were currently enrolled in a clinical trial while a greater proportion o f the
nonparticipants (95.1%) indicated they were not currently enrolled in a clinical trial.
The fourth aspect of characteristics of current and past participation in clinical
research trials was, “If you said “No” to ever been, previously, or currently enrolled in a
clinical trial, and you were asked to participate in a clinical trial in the future, would you
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participate?” This was accomplished using the Chi-square test of independence to
determine if the two variables (whether or not they had participated and whether or not
they would participate in a future clinical trial, if asked to do so) were independent. The
resulting calculated Chi-square value (x2a>= -07, g = .79) was not significant, indicating
that the two variables were independent.
The fifth aspect of characteristics of current and past participation in clinical
research trials was whether or not the respondents had ever decided not to participate in
a clinical trial after being eligible. For the participant group, less than one fourth (n = 24,
15.6%) of respondents indicated that they had decided not to participate in a clinical trial
after being eligible. In contrast, more than one fourth of nonparticipants (n = 56,26.2%)
indicated that they had decided not to participate in a clinical trial after being eligible (see
Table 31).
Table 31
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not
African Americans Decided Not to Participate After Being Eligible
Have vou ever decided not to participate
in a clinical trial after being eligible?

sfote.

x2(d=

Participation Status
Participant

Nonparticipant

Yes

24
15.6%

56
26.2%

No

130
84.4%

158
73.8%

Total

154
100%

214
100%

5.90, g = .0I5

The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they ever decided not to participate in a clinical trial after
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being eligible. This was accomplished using the Chi-square test of independence to
determine if the two variables (whether or not they had participated and whether or not
they ever decided not to participate in a clinical trial after being eligible) were independ
ent. The resulting calculated Chi-square value (x2n)= 5.90, g = .015) was significant,
indicating that the variables were not independent. The nature o f the association
between the variables was such that a smaller proportion of the participants (15.6%)
indicated they decided not to participate in a clinical trial after being eligible while a
greater proportion of the nonparticipants (26.2%) indicated they had decided not to
participate in a clinical trial after being eligible.
The sixth aspect of characteristics of current and past participation in clinical
research trials was to select the primary reason respondents decided not to participate in
a clinical trial after being eligible. For the participant group, the largest group (n = 5,
25.0%) of respondents indicated “Other” as the primary reason they decided not to parti
cipate in a clinical trial after being eligible. For the nonparticipants, the largest group (n
= 17,30.4%) of respondents indicated “Changed jobs, schedule would not permit” (see
Table 32) as their primary reason for deciding not to participate after being eligible.
There was a total of 76 individuals responding to this aspect of clinical research partici
pation status of which 17 indicated “Other” as their reason for not participating. Refer
to Appendices D and E (question number 37) for a complete listing o f participant and
nonparticipant responses.
The next part of this objective was to compare the participant and nonparticipant
groups on responses to the question, “If yes, what is the primary reason that you decided
not to participate in a clinical trial.” Table 32 clearly indicates that the numbers required
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Table 32
Crosstabulation o f Clinical Research Trial Participation Status and If Yes. Primary
Reason African A m ericans Decided Not to Participate
If yes, what is the primary reason that you decided
not to participate in the clinical trial?

Participation Status
Participant

Nonparticipant

Other*

5
25.0%

12
21.4%

Changed jobs, schedule would not permit

3
15.0%

17
30.4%

Live too far

3
15.0%

9
16.0%

Too much effort involved

3
15.0%

5
8.9%

Too many lab tests required

3
15.0%

3
5.4%

Changed mind, due to fear

2
10.0%

10
17.9%

Work too far

I
5.0%

-0-

Total

20
56
100%
100%
"See Appendices D and E for a complete list of other reasons reported by respondents.
to conduct the Chi-square test of independence were not adequate and therefore, no
reason to run the test to determine if the two variables (whether or not they had
participated and primary reason decided not to participate) were independent.
Objective two (e) was to describe and compare African Americans who have par
ticipated in clinical research trials and those who have not participated in clinical research
trials based on their exposure to selected experiences which are preliminary to participa-
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tion in clinical research trials. A total of four selected experiences preliminary to partici
pation in clinical research trials were examined as part of this objective. The first
experience was whether or not the respondents received any verbal or written materials
that described what the clinical trial was about and what needed to be done. For the
participant group, the majority (n = 137,88.4%) of respondents indicated that they
received verbal or written materials that described what the clinical trial was about and
what needed to be done. In contrast, only slightly more than half of the nonparticipants
(n = 105,50.2%) indicated that they had received verbal or written materials that
described what the clinical trial was about and what was needed to be done (see Table
33).
Table 33
Onsstahulation of Clinical Research Trial Exposures and Whether or Not African
A m ericans Indicated They Received Anv Verbal or Written Materials
Participation Status

Did you receive any verbal or written
materials that described what the clinical
trial was about and what you needed to
do?

Participant

Nonparticipant

Yes

137
88.4%

105
50.2%

No

10
6.5%

88
42.1%

Unsure

8
5.1%

16
7.7%

Total

155
100%

209
100%

Mote. x2(2)= 62.34, j>< .001
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The next part of this objective was to compare the participant and nonparticipant
groups on whetheror not they received any verbal or written materials that described
w. .c the clinical trial was about and what needed to be done. This was accomplished
using the Chi-square test of independence to determine if the two variables (whether or
not they participated and whether or not they received any verbal or written materials
that described what the clinical trial was about and what needed to be done) were
independent. The resulting Chi-square value (x2<2>= 62.34, g < .001) indicated that the
variables were not independent. The nature of the association between the variables was
such that a greater proportion of the participants indicated that they had received verbal
or written materials that described what the clinical trial was about and what needed to
be done while a greater proportion of the nonparticipants indicated that they had not
received any verbal or written materials describing what the clinical trial about and what
was needed to be done.
The second exposure to selected experiences which are preliminary to participa
tion in clinical research trials was whether or not respondents talked to family or friends
before making their decision to participate or not participate in a clinical trial. For the
par- ticipant group, almost half (n = 75,48.1%) of respondents indicated that they talked
to family or friends before making their decision to participate or not participate in a
clinical trial. In contrast, only slightly more than one fourth o f the nonparticipants (n 98,27.9%) indicated that they talked to family or friends before making their decision to
participate or not participate in a clinical trial (see Table 34).
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Table 34
Crosstabulation of Clinical 'Research Trial Exposures and Whether or Not African
A m ericans Indicated They Talked to Family or Friends Before Making Their Decision to
Participate or Not Participate
Participation Status
Did you talk to family or friends before
m aking your decision to participate or not
Participant
Nonparticipant
participate?
Yes

75
48.1%

58
27.9%

No

77
49.4%

140
67.3%

Unsure

4
2.5%

10
4.8%

Total

156
100%

208
100%

sfote. X2<2)= 15.93,p < .001
The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they talked to family or friends before making their decision to
participate or not participate in a clinical trial. This was accomplished using the Chisquare test of independence to determine if the two variables (whether or not they had
participated and whether or not they talked to family or friends before making their deci
sion to participate or not participate) were independent. The resulting calculated Chisquare value (x2(2)= 15.93, p < .001) indicated that the variables were not independent
The nature of the association between the variables was such that more of the partici
pants indicated that they talked to family or friends before making their decision to parti
cipate or not participate while the majority of the nonparticipants indicated they did not
talk to family or friends before making their decision to participate or not participate in a
clinical trial.
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The third exposure to selected experiences which are preliminary to participation
in clinical research trials was whether or not the respondents talked to their doctor
before making their decision to participate or not participate in a clinical trial. For the
participant group, less than one fifth (n = 29, 18.6%) of respondents indicated that they
talked to their doctor before making their decision to participate or not participate in a
clinical trial. Slightly more than one tenth of the nonparticipants (n = 26, 12.4%)
indicated that they talked to their doctor before making their decision to participate or
not participate in a clinical trial (see Table 35).
Table 35
Crosstabulation of Clinical Research Trial Exposures and Whether or Not African
Americans Indicated They Talked to Their Doctor Before Making Their Decision to
Participate or Not Participate
Did you talk to your doctor before
making your decision to participate or not
participate?

Participation Status
Participant

Nonparticipant

Yes

29
18.6%

26
12.4%

No

122
78.2%

176
84.2%

Unsure

5
3.2%

7
3.3%

Total

156
100%

209
100%

Note. x2f>)= 2.64, p = .27
The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they talked to their doctor before making their decision to
participate or not participate in a clinical trial. This was accomplished using the Chi-
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square test of independence to determine if the two variables (whether or not they had
participated and whether or not they talked to their doctor before making the decision to
partici- pate or not participate in a clinical trial) were independent. The resulting
calculated Chi-square value (x2o)= 2.64, g = .27) was not significant, indicating that the
two variables were independent
The fourth exposure to selected experiences which are preliminary to
participation in clinical research trials was whether or not the respondents had a family
history of the disease being researched that prompted their decision to participate or not
participate in a clinical trial. For the participant group, almost half (n = 71,47.0%) of
the respondents indicated that they had a family history of the disease being researched
that prompted their decision to participate or not participate in a clinical trial. In
addition, a little more than a third of the nonparticipants (n = 78,37.3%) indicated that
they had a family history of the disease being researched that prompted their decision to
participate or not participate in a clinical trial (see Table 36).
The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they had a family history of the disease being researched that
prompted their decision to participate or not participate. This was accomplished using
the Chi-square test of independence to determine if the two variables (whether or not
they had participated and whether or not they had a family history of the disease being
researched that prompted their decision to participate or not participate in a clinical trial)
were independent. The resulting calculated Chi-square value (x2(2)= 3.67, g = .16) was
not significant, indicating that the two variables were independent.
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Table 36
Crosstabulation of Clinical Research Trial Exposures and Whether or Not African
Americans Indicated They Had a Family History of the Disease That Prompted Their
Decision to Participate or Not Participate
Did you have a family history of the
disease being researched that prompted
your decision to participate or not
participate?

Participation Status
Participant

Nonparticipant

Yes

71
47.0%

78
37.3%

No

71
47%

113
54.1%

Unsure

9
6.0%

18
8.6%

Total

151
100%

209
100%

Note, x2r ) = 3.67. p = . 16
Objective two (f) was to describe and compare African Americans who have par
ticipated in clinical research trials and those who have not participated in clinical research
trials on their perceptions regarding the need for selected changes in preparation for
participation in clinical research trials. The first step in this process was to describe the
research respondents on their perceptions regarding the need for selected changes in
preparation for participation in clinical research trials. The perceptions regarding the
need for selected changes in preparation for participation in clinical research trials were
measured using six items to which respondents were asked to respond using a five point
Likert-type scale. The item with which the participant group most strongly agreed was,
“Hearing about the good things that have been discovered from clinical trials” (Mean =
4.39) (see Table 37). The item which participants were found to exhibit the lowest level
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of agreement with was, “Informational meeting about the clinical trial presented by
African Americans” (Mean = 4.00). The nonparticipants in the study reported the
highest level o f agreement with the same item as the participant group. This item was
“Hearing about the good things that have been discovered from clinical trials” (Mean =
4.35) (see Table 37). However, the item with which nonparticipants expressed the
lowest level of agreement was, “Informational meeting about the clinical trial presented
by the nurse” (Mean = 3.82).
To accomplish the second aspect of this objective, the researcher needed to com
pare the participants and nonparticipants on their perceptions regarding the need for
selected changes in preparation for participation in clinical research trials. However, to
conduct individual statistical comparisons on each of the items individually would have
created an unacceptably inflated alpha level due to the inflation of experiment-wise error.
Therefore, to accomplish this task, the researcher utilized the underlying construct and
the corresponding sub-scale score derived from the factor analysis reported in objective
one.
When the sub-scale score for perceptions regarding the need for selected changes
in preparation for participation in clinical research trials was compared by participation
status o f respondents using the independent samples t-test procedure, the results showed
that the two groups were not significantly different ( t381= 1.176, p = .24). There was
one scale score regarding the perceived need for selected changes in preparation for
participation in a clinical research trial factor labeled by the researcher as “Ideas/Sugges-
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Table 37
Perceptions Regarding th e N eed for Selected C hanges in Preparation for C linical
R esearch T rials A m ong A frican A m ericans hv Participation Status

Participants

Item

Nonparticipants

Mean*

SD

Mean*

SD

Hearing about the good
things that have been dis
covered from clinical trials.

4.39

.79

4.35

.75

Informational meeting
about the clinical trial
presented by the physician.

4.39

.69

4.18

.90

Talking to other African
Americans who have taken
part in clinical trials.

4.17

.92

4.19

.94

Informational meeting
about the clinical trial pre
sented by the nurse.

4.05

.94

3.82

.99

TV shows or videotapes
with African Americans in
clinical trials.

4.01

1.00

4.00

1.01

4.00
.97
Informational meeting
1.00
3.96
about the clinical trial pre
sented by African Ameri
cans.
•Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.504.49 = agree; 4.50-5.00 = strongly agree.
tions” with a mean score of 4.17 (SD = .63) for the participant group and 4.08 (SD .70) for the nonparticipant group.
Objective two g (i) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials based on their gender. The majority (n = 121,76.6%) o f the respondents
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in the participant group were female and the majority (n = 187,82.0%) of the
respondents in the nonparticipant group were female (see Table 38).
Table 38
Description of Participants and Nonparticipants in Clinical Research Trials bv Gender
Among African Americans
Nonparticipants

Participants

Gender
n

%

n

%

Female

121

76.6

187

82.0

Male

37

23.4

41

18.0

158

100.0

228

100.0

Total
Note. x2(i)= 1-71. p = .20

The second aspect of this objective was to compare the participant and nonparti
cipant groups based on gender. This was accomplished using the Chi-square test of
independence to determine if the two variables (whether or not they participated and
whether they were male or female) were independent. The resulting calculated Chisquare value (X2(i)= 1-71, p = .20) was not significant, indicating that the two variables
were independent.
Objective two g (ii) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials based on their age. The first aspect was to describe the participant and
nonparticipant groups based on age. The largest number (n = 67,42.4%) of the
respondents in the participant group were in the 46-55 year age group. The largest
number (n = 70,30.8%) of the respondents in the nonparticipant group were in the 3645 year age group. The second largest number (n = 37,23.4%) of respondents in the
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participant group were in the 36-45 year age group. The second largest number (n = 66,
29.1%) of the respondents in the nonparticipant group were in the 46-55 year age group
(see Table 39).
Table 39
Description of Participants and Nonparticipants in Clinical Research Trials by Age
Among African Americans
Nonparticipants

Participants

Age Group
n

%

n

%

< 18 years

1

0.6

0

0.0

18-25 years

12

7.6

11

4.8

26-35 years

11

7.0

44

19.4

36-45 years

37

23.4

70

30.8

46-55 years

67

42.4

66

29.1

56-65 years

25

15.8

26

11.5

66 years and over

5

3.2

10

4.4

100.0

227*

100.0

158
Total
Mote, x2<6)= 21.02, g = .002
•One respondent did not answer this item.

The next part of this objective was to compare the participant and nonparticipant
groups on whether or not they participated in clinical research trials based on age. This
was accomplished using the Chi-square test of independence to determine if the two
variables (whether they participated and age group) were independent.

The resulting

calculated Chi-square value (x2(6)= 21.02, j> = .002) indicated that the variables were not
independent. The nature of the association between the variables was such that a greater
proportion o f the participants were in the 46-55 year and the 56-65 year age categories
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while a greater proportion of the nonparticipants were in the 26-35 year and the 36-45
year age range categories.
Objective two g (iii) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials based on their marital status. The first aspect was to describe the partici
pant and nonparticipant groups based on marital status. Half (n = 79,50.0%) of the
respondents in the participant group indicated they were married. Approximately half (n
= 113,49.8%) of the respondents in the nonparticipant group indicated they were
married. The next largest group (n = 36,22.8%) of the respondents in the participant
group indicated they were divorced/separated. More than one fourth (n = 62,27.3%) of
the respondents in the nonparticipant group indicated they were divorced/separated (see
Table 40).
The second aspect of this objective was to compare the participant and nonparti
cipant groups on whether or not they participated in clinical research trials based on
marital status. This was accomplished using the Chi-square test of independence to
determine if the two variables (whether they participated and whether they were married,
divorced/ separated, never married, or widowed) were independent. The resulting
calculated Chi-square value (x2(3)= 1.56, g = .67) was not significant, indicating that the
two variables were independent.
Objective two g (iv) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials based on their education level. The first aspect was to describe the parti
cipant and nonparticipant groups based on education level. Less than one third (n = 47,
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Table 40
Description of Participants and Nonparticipants in Clinical Research Trials bv Marital
Status

A m rtn p r

African Americans

Nonparticipants

Participants

Marital Status
n

%

n

%

Married

79

50.0

113

49.8

Divorced/Separated

36

22.8

62

27.3

Never Married

31

19.6

39

17.2

Widowed

12

7.6

13

5.7

100.0

227*

100.0

158
Total
Note, x2(3)= 1.56, g = .67
"One respondent did not answer to item.

29.9%) o f the respondents in the participant group indicated 1-3 years college, business
or technical school education level. Almost half (n = 104,45.8%) of the respondents in
the nonparticipant group indicated 1-3 years college, business or technical school
education level. Almost one fourth (n = 38,24.2%) of the respondents L i the participant
group indicated they had college degrees. Less than one fifth (n = 44,19.4%) of the
respondents in the nonparticipant group indicated they had college degrees (see Table
41).
The next part of this objective was to compare the participant and nonparticipant
groups on their level of education. This was accomplished using the Chi-square test of
independence to determine if the two variables (whether they participated and education
level) were independent.

The resulting calculated Chi-square value (x2(j)= 13.47, g =

.02) indicated that the variables were not independent The nature of the association
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Table 41
Description o f Participants and Nonparticipants in Clinical Research Trials bv Education
Level Among African Am ericans
Participants

Education Level

Nonparticipants

n

%

n

%

Grades 0-8

3

2.0

1

0.4

Some High School

11

7.0

16

7.0

High School Diploma/GED

22

14.0

31

13.7

1-3 years college, business
or technical school

47

29.9

104

45.8

College degree

38

24.2

44

19.4

Post graduate degree

36

22.9

31

13.7

100.0

227b

100.0

Total
157“
Note. x 2,s )= 13.47,p = .02
*One respondent did not answer to item.
bOne respondent did not answer to item.

between the variables was such that a greater proportion of the participants reported
college degree and post graduate degree as their highest level of education completed.
Among the nonparticipants, a greater proportion indicated 1-3 years college, business or
technical school as their highest level of education completed.
Objective two g (v) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials based on their employment status. The first aspect was to describe the
participant and nonparticipant groups based on employment status. The majority (n =
111, 70.3%) o f the respondents in the participant group were employed full time. Like-
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wise, the majority (n = 160,70.5%) of the respondents in the nonparticipant group were
employed full time (see Table 42).
Table 42
Description of Participants and Nonparticipants in Clinical Research Trials bv Employ
ment Status Among African Americans
Employment Status

Participants

Nonparticipants

n

%

n

%

Employed full time

111

70.3

160

70.5

Employed part-time

12

7.6

19

8.4

Retired

13

8.2

19

8.4

Unemployed

17

10.8

16

7.0

Medical disability

5

3.1

13

5.7

100.0

227"

100.0

Total
158
Slote. X2(4)=2.88, £>= .58
“One respondent did not answer this item.

The second aspect of this objective was to compare the participant and nonparti
cipant groups based on employment status. This was accomplished using the Chi-square
test o f independence to determine if the two variables (whether they participated and
whether they were employed full time, part-time, retired, unemployed, or medically
disabled) were independent. The resulting calculated Chi-square value (x2<4)= 2.88, jj =
.58) was not significant, indicating that the two variables were independent.
Objective two g (vi) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials based on their approximate household income. The first aspect was to
describe the participant and nonparticipant groups based on approximate household in92
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come. The largest number (n = 37,24.2%) of the respondents in the participant group
reported an approximate household income range of $70,000 and over per year. The
largest number (n = 48, 22.0%) of the respondents in the nonparticipant group reported
an approximate household income in the range of $20,000 - $29,999 per year (see Table
43).
Table 43
Description of Participants and Nonparticipants in Clinical Research Trials bv Household
Income Among African Americans
Household Income

Participants

Nonparticipants

n

%

n

%

< $10,000 per year

17

11.0

35

16.1

$10,000-$19,999

24

15.7

38

17.4

$20,000-$29,999

28

18.3

48

22.0

$30,000-$39,999

16

10.5

26

11.9

$40,000-$49,999

13

8.5

17

7.8

$50,000-$59,999

18

11.8

24

11.0

$70,000 and above

37

242

30

13.8

100.0

2I8b

100.0

Total
153*
Note, x2<6)= 8.02,p =.24
‘Five respondents did not answer this item.
'Twenty respondents did not answer this item.

The second aspect o f this objective was to compare the participant and nonparti
cipant groups on approximate household income. This was accomplished using the Chisquare test of independence to determine if the two variables (whether they participated
and level of household income) were independent The resulting calculated Chi-square
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value (x2(6>~ 8.02, £ = .24) was not significant, indicating that the two variables were
independent.
Objective two g (vii) part I was to describe and compare African Americans who
have participated in clinical research trials and those who have not participated in clinical
research trials based on distance they lived from the research center. The first aspect
was to describe the participant and nonparticipant groups based on distance lived from
the research center. The largest number (n = 4 9 ,3 1.6%) of respondents in the partici
pant group indicated that they lived within 15 miles of the research center. Likewise, the
largest number (n = 66,29.6%) of respondents in the nonparticipant group lived within
15 miles o f the research center (see Table 44).
Table 44
Description of Participants and Nonparticipants in Clinical Research Trials bv Distance
Live From Research Center Among African Americans
Distance Live from
Research Center

Participants

Nonparticipants

n

%

n

%

Within 3 miles

27

17.4

30

13.4

Within 7 miles

41

26.4

61

27.4

Within 15 miles

49

31.6

66

29.6

Within 20 miles

19

12.3

33

14.8

> 20 miles

19

12.3

33

14.8

100.0

223b

100.0

Total
155“
Note. x2(4>= 196, p = .74
‘Three respondents did not answer this item.
bFive respondents did not answer this item.

The next part of this objective was to compare the participant and nonparticipant
groups based on distance they lived from the research center. This was accomplished
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using the Chi-square test of independence to determine if the two variables (whether they
participated and distance lived from the research center) were independent. The result
ing calculated Chi-square value (x2<4)= 1-96, p = .74) was not significant, indicating that
the two variables were independent.
Objective two g (vii) part II was to describe and compare African Americans
who have participated in clinical research trials and those who have not participated in
clinical research trials based on distance they worked from the research center. The first
aspect was to describe the participant and nonparticipant groups based on distance
worked from the research center. The largest number (n = 49,35.5%) o f the respon
dents in the participant group worked within 7 miles o f the research center and the two
response categories with the largest numbers (n = 50,26.3% each) of the respondents in
the nonparticipant group worked within 7-15 miles of the research center (see Table 45).
The next part of this objective was to compare the participant and nonparticipant
groups based on distance worked from the research center. This was accomplished
using the Chi-square test of independence to determine if the two variables (whether they
participated and distance worked from the research center) were independent. The
resulting calculated Chi-square value (x2,5>= 12.29, j> = .03) indicated that the variables
were not independent The nature of the association between the variables was such that
greater proportions of the participants indicated that they worked at the research center
and within 7 miles of the center. In contrast, among the nonparticipants, greater propor-
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Table 45
Description of Participants and Nonparticipants in Clinical Research Trials bv Distance
Work From Research Center A m ong African Americans
Distance Work from
Research Center

Participants

Nonparticipants

n

%

n

%

At research center

10

7.2

3

1.6

Within 3 miles

25

18.1

36

19.0

Within 7 miles

49

35.5

50

26.3

Within 15 miles

28

20.3

50

26.3

Within 20 miles

11

8.0

24

12.6

> 20 miles

15

10.9

27

14.2

190b

100.0

Total
138*
100.0
Mote. X2(S)= 12.29, p = .03
"Ten respondents did not answer to this item.
Thirty eight respondents did not answer to this item.

tions indicated that they worked within 15 miles, within 20 miles, and more than 20 miles
from the research center.
Objective two g (viii) was to describe and compare African Americans who have
participated in clinical research trials and those who have not participated in clinical
research trials based on overall health status. The first aspect was to describe the partici
pant and nonparticipant groups based on overall health status. The largest number (n =
55,34.8%) of respondents in the participant group indicated their overall health was
good. The largest number (n = 97,42.7%) o f respondents in the nonparticipant group
indicated their overall health was good (see Table 46).
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Table 46
Description of Participants and Nonparticipants in Clinical Research Trials bv Overall
Health Status Among African Americans
Participants

Overall Health Status

Nonparticipants

n

%

n

%

Good

55

34.8

97

42.7

Very Good

54

34.2

72

31.7

Excellent

32

20.2

33

14.5

Fair

17

10.8

19

8.4

Poor

0

0.0

6

2.7

100.0

227*

100.0

158
Total
Note, x2d)= 8.20. p = .09
“One respondent did not answer to this item.

The next part of this objective was to compare the participant and nonparticipant
groups based on their overall health status. This was accomplished using the Chi-square
test of independence to determine if the two variables (whether they participated and
overall health status) were independent. The resulting calculated Chi-square value (x2(4)
= 8.20, p = .09) was not significant, indicating that the two variables were independent.
Objective Three
Objective three of the study was to determine if a model existed that significantly
increased the researcher’s ability to correctly classify subjects on their participation
status in clinical research trials based on (1) knowledge of clinical research processes, (2)
perceptions of clinical research purposes and procedures, (3) advantages and disadvan
tages for the individual of participation in clinical research trials, (4) characteristics o f
current and past participation in clinical research trials, (5) exposure to selected experi97
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ences which are preliminary to participation in clinical research trials, (6) perceptions
regarding the need for selected changes in preparation for participation in clinical

research trials, and (7) the following selected personal demographic characteristics: (i)
gender, (ii) age, (iii) marital status, (iv) education level, (v) employment status, (vi)
household income, (vii) distance from research center, and (viii) overall health status.
To accomplish objective three of the study, the researcher examined the data for
the existence of a statistically significant discriminant model. This model included all
available information and was for the purpose of maximizing the researcher’s ability to
correctly classify subjects on the outcome measure of whether or not African Americans
participated in a clinical research trial. In addition, this model included all summary
perceptual items measured in the study as well as selected demographic information.
The alpha level was established a'priori at .05 and substantive significance of the
discriminant model in this study was defined as a 25% improvement over chance, the
acceptable margin for a two category variable (Barrick and Warmbrod, 1988).
The Discrim inant Model
The first step in examining the discriminant model was to compare the groups on
each of the independent variables. This information is presented in Table 47.
Comparisons were made using the one-way analysis of variance procedure. Of the 43
factors on which comparisons were made, the groups (participants and nonparticipants)
were found to be significantly different on 16 variables. The variables on which the
groups were most different were: knowledge factor one (“Information Provided”),
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Table 47
Comparison of Mean Values for Discriminating Variables in the Model bv Participation
Status Among African Americans
Discriminating
Variable

Group

F ratio

E

Participants

Nonparticipants

VERBALY
(Did you receive
any verbal
materials, Yes)

m 1.90
sd .30

m 1.54
sd .50

51.90

<.01

VERBALN
(Did you receive
any verbal
materials, No)

1.06
.23

1.37
.48

44.25

<.01

AGEGRP4
(46-55 years)

.48
.50

.25
.43

18.22

<.01

AGEGRP2
(26-35 years)

.06
.25

.25
.43

17.96

<.01

KFACTOR1
(Information
Provided)

4.22
.66

3.85
.79

17.31

<.01

DISADVAN
(Drawbacks)

2.74
.84

3.17
.92

16.20

<.01

KFACTOR2
(Awareness)

4.58
.47

4.33
.58

16.17

<.01

FAMILYY
(Did you talk to
family, Yes)

1.46
.50

1.24
.43

15.70

<.01

PFACTOR1
(Participation
Benefits)

4.40
.54

4.18
.55

10.53

.001

FAMILYN
(Did you talk to
family, No)

1.52
.50

1.70
.46

9.22

.003

(Table continues)
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WORK7
(Within 7 miles)

m .40
sd .49

ra .24
sd .43

8.62

.004

ADVAN
(Primary Benefits)

3.98
.61

3.79
.55

7.72

.00

WIDOWED
(Marital Status)

1.07
.26

1.02
.13

5.33

.02

PFACTOR2
(Prevention)

3.34
1.07

3.05
1.05

5.24

.023

SOMECOLL
(1-3 yrs. College)

.32
.47

.45
.50

5.20

.02

HEALTH
STATUS

2.31
.86

2.52
.89

4.27

.04

POSTGRAD
(Post graduate)

.23
.43

.15
.35

3.72

.06

HISTORYY
(Did you have a
family history, Yes)

1.47
.50

1.36
.48

3.59

.06

WORK20
(Within 20 miles)

.06
.25

.13
.33

3.10

.08

WORK 15
(Within 15 miles)

.20
.40

.28
.45

2.63

.11

LIVE3
(Within 3 miles)

.17
.38

.11
.31

2.20

.14

LESS10
(Household income
<$10,000/year)

.08
.27

.13
.34

2.00

.16

WORKMORE
(> 20 miles)

.09
.29

.14
.35

1.75

.19

AGEGRP3
(36-45 years)

.27
.45

.35
.48

1.67

.20

LIVE20
(Within 20 miles)

.13
.34

.18
.39

1.47

.23

(Table continues)
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UNEMPLOY
(Unemployed)

m 1.04
sd .20

m 1.02
sd .13

1.29

26

RETIRED
(Employment
status)

1.05
.22

1.02
.15

1.23

.27

DOCTORY
(Did you talk to
your doctor, Yes)

1.15
.36

1.11
.31

1.23

.27

fflSTORYN
(Did you have a
family history, No)

1.48
.50

1.54
.50

.87

.35

COLLEGE
(College degree)

.26
.44

.22
.41

.62

.43

RECRUIT

4.14
.65

4.08
.64

.61

.44

LIVEMORE
(More than 20
miles)

.10
.31

.13
.34

.54

.46

PARTTIME
(Employment
status)

1.07
.26

1.10
.30

.53

.47

GENDER

1.77
.43

1.80
.40

.48

.49

TEN20
(Household
income, $10$ 19,999/year)

.15
.35

.18
.38

.48

.49

DIVORCED
(Marital status)

1.23
.43

1.27
.44

.40

.53

THIRTY40
(Household
income, $30$39,999/year)

.12
.33

.15
.35

.36

.55

LIVE 15
(Within 15 miles)

.32
.47

.30
.46

.22

.64

(Ideas/Suggestions')

(Table continues)
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DOCTORN
(Did you talk to your
doctor, No)

m 1.83
sd .38

m 1.85
sd .36

.17

.68

AGEGRP5
(56-65 years)

.10
.30

.08
.28

.12

.73

DISABIL
(Medical disability)

1.02
.13

1.01
.11

.08

.77

TWENTY30
(Household income,
$20-$29,999/year)

.19
.40

.21
.41

.07

.79

SINGLE
(Marital status)

1.19
.39

1.19
.40

.03

.86

knowledge factor two (“Awareness”), disadvantage factor (“Drawbacks”), whether or
not they responded “Yes” to the question “Did you receive any verbal or written
materials that described what the clinical trial was about and what you would need to
do,”whether or not they responded “No” to the question “Did you receive any verbal or
written materials that described what the clinical trial was about and what you would
need to do,”whether or not they responded “Yes” to the question “Did you have a family
history o f the disease being researched that prompted your decision to participate or not
participate,” whether or not they responded “No” to the question “Did you have a family
history o f the disease being researched that prompted your decision to participate or not
participate, whether or not they were in the 26-35 year age group, and whether or not
they were in the 46-55 year age group.
After comparing the discriminating variable means, the next step in conducting a
discriminant analysis was to examine the independent variables to be included in the
analysis for the presence of multicollinearity. Several techniques are available for con102
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ducting this assessment, however, Lewis-Beck (1980) indicates that the preferred
method for assessing multicollinearity is to, “Regress each independent variable on all the
other independent variables” (p. 60). This procedure takes into account the relationship
of each of the independent variables with all of the other independent variables. If any of
the cumulative R2 values are near 1.0, there is high multicollinearity. It is also important
to note that values which are considered to be high in multicollinearity are more stringent
for studies which have small sample sizes, while larger sample sizes reduce the serious
ness o f the consequences of multicollinearity. When the cumulative R2 was checked for
each of the independent variables regressed on all the other included independent
variables, no instances of excessive multicollinearity were found.
In the third step, the computed standardized canonical discriminant function co
efficients were examined. The centroids for the groups were determined to be .75 for
the participant group and -.56 for the nonparticipant group. A total of 7 factors entered
the discriminant model and produced an overall canonical correlation of R = .544. This
indicated that the combination of the 7 factors in the model explained a total of 29.6%
(R2) o f the variability in whether or not African Americans participated in clinical
research trials.
The factors which were found to have the highest standardized coefficients were
(1) knowledge factor 2 labeled by the researcher as “Awareness”, (2) disadvantage
factor labeled by the researcher as “Drawbacks”, (3) “Did you receive any verbal or
written materials that described what the clinical trial was about and what you would
need to do” (whether or not they responded “Yes”), (4) whether or not their marital
status was Widowed, (5) whether or not they were in the 26-35 year age group, (6)
103
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whether or not they were in the 46-55 year age group, and (7) whether or not their place
of employment was within 15 miles of the Pennington Center. Each of the factors that
entered this model was statistically significant. When the structure coefficients were
examined for substantive significance, five of the factors were found to meet the criteria
of substantive significance. This criteria includes all factors which are one-half or larger
o f the magnitude of the largest structure coefficient. However, since the purpose of this
model was to increase the researcher’s ability to correctly classify subjects on their
participation status in clinical research trials, all variables were retained that met the
statistical criteria for inclusion (see Table 48).
Table 48
Summary Data for Stepwise Discriminant Analysis (n = 3111
Variables

b

s

VERBALY
(Did you receive
any verbal
materials, Yes)

.61

.66

KFACTOR2
(Awareness)

.41

.37

AGEGRP2
(26-35 years)

.36

-39

DISADVAN
(Drawbacks)

-.32

-.37

Discriminant
Group
Participants

Centroids
.75

Nonparticipants

-.56

(Table continues)

104

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

WIDOWED
(Marital Status)

.28

.21

WORK 15
(Within 15 miles)

-.27

-.15

AGEGRP4
(46-55 years)

.25

.39

Sieen value
Rc
Wilk’s Lambda
.420
.544
.704
b = standardized discriminant function coefficient
s = within group structure coefficient
Rc = canonical correlation coefficient
Finally, the correctly classified cases were examined. Seventy five (19.4%) o f the
subjects were eliminated from the calculation of the discriminant model due to at least
one missing discriminating variable. A total of 311 respondents were used in the
calculated discriminant model. The researcher directed the classification portion of the
program to classify all cases by using the mean-substitution function for missing values.
This procedure functions as an additional check for the effectiveness o f the model. The
model correctly classified 74.6% of the cases analyzed (see Table 49).
Table 49
Classification of Cases bv the Discriminant Model for Participation Status of Potential
African Americans in Clinical Research Trials
Actual Group

No. of Cases

Predicted Group
Participants

Nonparticipants

Participants

135

108
80.0%

27
20.0%

Nonparticipants

176

52
29.5%

124
70.5%

Note. Percent o f cases correctly classified: 74.6%.
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To determine the substantive value of the derived discriminant model, the
researcher used the Tau statistic. This statistic measures the proportional reduction in
error and provides a standardized measurement of improvement from the model for any
number of dependent variable groups (Barrick and Warmbrod, 1988). It is calculated
using the following formula:
tau=

^ -E

pa

n -LP.n,

where: n,. = number of cases correctly classified
n = total number of cases
Pi = prior probability of group membership
nj = number of cases in group i
A measurement of 25 or higher is generally considered to be indicative of a meaningful
model (Barrick and Warmbrod, 1988). The Tau value for this discriminant model was
computed as follows:
tau=

De-Epft
n -LPA

tau=

232 - (67.5 + 88)
311 -(67.5 + 88)

tau =

232 - 155.5
311-155.5
76.5
155.5

tau =

tau = 49.2
The 49.2 derived Tau was greater than the minimum value which indicates that the
model is meaningful.
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CHAPTER 5
SUMMARY
The purpose of this study was to gain an understanding of the knowledge,
attitudes, and beliefs African Americans have that support decisions to either participate
or not participate in a clinical trial.
Objectives
The following specific objectives were formulated to guide the researcher:
1. To describe African Americans who were potential participants in clinical research
trials on each of the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in clinical
research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in clinical
research trials;
f. Perceptions regarding the need for selected changes in preparation for par
ticipation in clinical research trials; and
g. Perceptions regarding the need for selected changes in preparation for par
ticipation in clinical research trials; and
h. The following selected personal demographic characteristics:
i.

Gender,

ii.

Age,
107
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iii.

Marital status,

iv.

Education level,

v.

Employment status,

vi.

Household income,

vii.

Distance from research center, and

viii.

Overall health status.

2. To describe and compare African Americans who have participated in clinical
research trials and those who have not participated in clinical research trials on each
of the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in clinical
research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in clinical
research trials;
f. Perceptions regarding the need for selected changes in preparation for par
ticipation in clinical research trials; and
g. The following selected personal demographic characteristics:
i.

Gender,

ii.

Age,

iii.

Marital status,

iv.

Education level.
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v.

Employment status,

vi.

Household income,

vii.

Distance from research center, and

viii.

Overall health status.

3. To determine if a model existed that significantly increased the researcher’s ability to
correctly classify volunteers on their participation status in clinical research trials
from the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in clinical
research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in clinical
research trials;
f. Perceptions regarding the need for selected changes in preparation for par
ticipation in clinical research trials; and
g. The following selected personal demographic characteristics:
i.

Gender,

ii.

Age,

iii.

Marital status,

iv.

Education level,

V.

Employment status,

vi.

Household income,
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vii.

Distance from research center, and

viii

Overall health status.

The survey method was utilized in this study. The target population was defined
as all African Americans age 18 and older who were potential participants in a clinical
trial. The accessible population were all African Americans in the Pennington Biomedi
cal Research Center’s Database from 1992-2000. The frame of the accessible population
was established as those who were currently enrolled at the time of the study, previously
participated, and those who did not participate in a clinical trial. The sample consisted of
100% of the defined accessible population frame.
A modified version of the questionnaire (Appendix B) “Perceptions of Participa
tion in Clinical Research” (McLean and Jensen, 1998) was utilized in conducting this
study. The original questionnaire was modified due to the relevance of questions
applicable to African Americans, length of the instrument, and the approximate time it
would take to complete. The modified version of the questionnaire consisted of 8 pages,
58 questions, and 7 sections.
The questionnaire was mailed to 3302 African American adults (770 participants
and 2532 nonparticipants) who were potential participants in a clinical trial at the
Pennington Biomedical Research Center during the years of 1992-2000. A letter of
introduction (Appendix A) accompanied the questionnaire. Along with instructions and
guidelines, the letter stressed the importance o f completing the survey. Participants were
asked to return questionnaires within two weeks after receiving. A total o f 386 (158
participants or 21 percent, and 228 nonparticipants or 9 percent) responded to the
questionnaire.
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The following is a summary of the major findings in the study:
1. Knowledge nf clinical research processes- Overall respondents most strongly
agreed with the item, "Volunteers can refuse to participate in a clinical trial".
When comparing the participant group to the nonparticipant group, the item
with which both groups strongly agreed was, "Volunteers can refuse to partici
pate in a clinical trial". However, the item with which the participant group
exhibited the lowest level of agreement was, "Volunteers are made aware of
any possible complications or side effects of taking part in a clinical trial." The
nonparticipant group expressed the lowest level of agreement with the item,
"Volunteers usually receive a cash stipend for participation in a clinical trial."
To further summarize these findings, the researcher utilized the underlying
constructs and the corresponding sub-scale scores derived from the factor
analysis conducted in objective one of the study. Two sub-scale scores for the
knowledge factor were derived. The first was labeled by the researcher as
"Information Provided”. The participant group reported significantly higher
levels of agreement in the "Information Provided" knowledge factor than did
the nonparticipants. The second knowledge factor, labeled as "Awareness" by
the researcher, produced similar results in that the participant group had a
significantly higher level of agreement with the items in the "Awareness”
knowledge factor than did the nonparticipants.
2. Perceptions of clinical research purposes and procedure- Overall respondents
most strongly agreed with the item, "Participation in a clinical trial can help
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future generations,” and the statement with which respondents least agreed
was, "Participation in a clinical trial can delay a disease.” To further
summarize these findings, the researcher utilized the underlying constructs and
the corresponding sub-scale scores derived from the factor analysis conducted
in objective one of the study. Two sub-scale scores for the perception factor
were derived. The first perception factor was labeled by the researcher as
"Participation Benefits.” The participant group reported significantly higher
levels of agreement with items in the "Participation Benefits" perception factor
than did the nonparticipants. For the second perception factor labeled by the
researcher as "Prevention,” the participant group had a significantly higher
level of agreement with the items in the "Prevention" perception factor than did
the nonparticipants.
3. Advantages for the Individual of Participation in Clinical Research Trials-

Overall respondents most strongly agreed with the item, "Doing something that
will help others,” and least agreed with the item, "Getting free medications.”
To further summarize these findings, the researcher utilized the underlying
constructs and the corresponding sub-scale scores derived from the factor
analysis conducted in objective one of the study. Only one sub-scale score was
derived and labeled by the researcher as, "Primary Benefits." The participant
group reported significantly higher levels of agreement with items in the
"Primary Benefits” advantage factor than did the nonparticipants. In addition,
respondents were asked to specify nther advantages they perceived for the
individual of participation in clinical research trials. The participant group
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specified, "Learn about medicine and body,” and "Meeting others" as other
advantages to participation in clinical trials. The nonparticipant group speci
fied, "Knowledge obtained is beneficial," and "If a clinical trial helps find a cure
for a particular disease," as other advantages to participation in clinical trials.
4. Disadvantages for the Individual nf Participation in Clinical Research TrialsOverall respondents most strongly agreed with the item, "Experiencing side
effects of the treatment," and least agreed with the item, "Being treated like a
"guinea pig" as disadvantages for the individual of participation in clinical
research trials. To further summarize these findings, the researcher utilized the
underlying constructs and the corresponding sub-scale scores derived from the
factor analysis conducted in objective one of the study. Only one sub-scale
score was derived and labeled by the researcher as, "Drawbacks." The nonpar
ticipant group reported significantly higher levels o f agreement with items in
the "Drawbacks" disadvantage factor than did the participants. In addition,
respondents were asked to specify other disadvantages they perceived for the
individual of participation in clinical research trials. The participant group
specified, "Dates and times can’t be changed or rescheduled, inconvenient,"
"Forcing someone to overeat to maintain a specific weight; many studies too
long," and "Trip to clinic" as other disadvantages for the individual o f partici
pation in clinical research trials. The nonparticipant group specified, "Risk to
your health," "Getting to clinic," "Time consuming; inconvenient," "Overcom
ing past atrocities where African Americans were deliberately infected (i.e.
syphilis virus)," and "Not knowing if you are receiving treatment or sugar pill"
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as other disadvantages for the individual of participation in clinical research
trials.
5. Characteristics of Current and Past Participation in Clinical Research TrialsSix aspects of clinical research participation status were examined. The first
aspect was whether or not the respondents had ever been asked to participate
in a clinical trial. The majority of the participant group indicated that they had
been asked to participate in a clinical trial. In contrast, the majority of the non
participant group indicated that they had not been asked to participate in a
clinical trial. The second aspect was whether or not the respondents had
previously participated in a clinical trial. The majority of the participant group
indicated that they had previously participated in a clinical trial. In contrast,
the majority of the nonparticipant group indicated that they had not previously
participated in a clinical trial. The third aspect was whether or not the respon
dents were currently enrolled in a clinical trial. The nature of the association
between the variable was such that a greater proportion of the participant
group indicated that they were currently enrolled in a clinical trial while a
greater proportion of the nonparticipants indicated that they were not currently
enrolled in a clinical trial. The fourth aspect was whether or not respondents
would participate in future clinical trials if they had said "No", to ever been,
previously, or currently enrolled in a clinical trial. There was no significant
difference in these two variables indicating that the two variables were inde
pendent. The fifth aspect was whether or not the respondents had ever decided
not to participate in a clinical trial after being eligible. The nature o f the
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association between the variables was such that a smaller proportion of the
participant group indicated they decided not to participate in a clinical trial
after being eligible while a greater proportion of the nonparticipants indicated
they had decided not to participate in a clinical trial after being eligible. The
sixth aspect of characteristics of current and past participation in clinical
research trials was to select the primary reason respondents decided not to
participate in a clinical trial after being eligible. Overall the reason respondents
most often identified was, "Changed jobs, schedule would not permit" as the
primary reason not to participate in a clinical trial. Respondents were also
asked to specify other primary reasons for choosing not to participate in a
clinical trial. The participant group indicated, "Busy schedule," "Illness in
family," "Was not selected,", and "Didn’t lose weight" The nonparticipant
group indicated, "Disqualification; eligibility criteria for the study," "Hours of
participation were during work hours," "No transportation,", and "Friend
talked me out of it" as primary reasons not to participate in a clinical trial. The
results of the respondents’ other specified responses were not significant,
indicating that the two variables (whether or not they had participated and if
yes, other primary reason decided not to participate after being eligible) were
independent.
6. Exposure to Selected Experiences Which are Preliminary to Participation in
Clinical Research Trials- A total o f four selected experiences preliminary to
participation in clinical research trials were examined. The first exposure was
whether or not the respondents received any verbal or written materials that
115

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

described what the clinical trial was about and what was needed to be done.
The nature of the association between the variables was such that a greater
proportion of the participant group indicated that they had received verbal or
written materials that described what the clinical trial was about and what was
needed to be done while a greater proportion of the nonparticipants indicated
that they had not received any verbal or written materials describing what the
clinical trial was about and what was needed to be done. The second exposure
to selected experiences, which are preliminary to participation in clinical
research trials, was whether or not respondents talked to family or friends
before making their decision to participate or not participate in a clinical trial.
The nature of the association between the variables was such that more of the
participant group indicated that they talked to family or friends before making
their decision to participate or not participate while the majority of the nonpar
ticipants indicated they did not talk to family or friends before making their
decision to participate or not participate in a clinical trial. The third exposure
was whether or not the respondents talked to their doctor before making their
decision to participate or not participate in a clinical trial. The two variables
(whether or not they participated and whether or not they talked to their
doctor before making the decision to participate or not participate in a clinical
trial) were not significant, indicating that the two variables were independent.
The fourth exposure was whether or not the respondents had a family history
of the disease being researched that prompted their decision to participate or
not participate in a clinical trial. The two variables (whether or not they
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participated and whether or not they had a family history o f the disease being
researched that prompted their decision to participate or not participate in a
clinical trial) were not significant, indicating that the two variables were
independent. In addition, respondents were asked to specify other exposures
to selected experiences, which are preliminary to participation in clinical
research trials. The largest response from the participant group was, "Having
family history o f disease,” and the two largest responses from the nonpartici
pant group were, "Never asked to participate,” and "Did not fit profile" as
other specified exposures to selected experiences, which are preliminary to
participation in clinical research trials.
7. Perceptions Regarding the Need for Selected Chances in Preparation for
Participation in Clinical Research Trials- Overall the statement with which the
respondents most strongly agreed was, "Hearing about the good things that
have been discovered from clinical trials," and least agreed was, "Informa
tional meeting about the clinical trial, presented by the nurse.” When compar
ing the participant group to the nonparticipant group, the item with which both
the participant and nonparticipant group most strongly agreed was, "Hearing
about the good things that have been discovered from clinical trials." The item
with which the participant group least agreed was, "Informational meeting
about the clinical trial presented by African Americans.” The item with which
the nonparticipant group least agreed was, "Informational meeting about the
clinical trial presented by the nurse." To further summarize these findings, the
researcher utilized the underlying constructs and the corresponding sub-scale
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scores derived from the factor analysis conducted in objective one o f the study.
Only one sub-scale score was derived and labeled by the researcher as, "Ideas/
Suggestions." When comparing the participant group to the nonparticipant
group based on the sub-scale score, there was no significant difference in the
two groups. In addition, respondents were asked to specify other perceptions
regarding the need for selected changes in preparation for participation in
clinical research trials. The largest response specified from the participant
group was, "More advertising in African American periodicals," "TV
commercials with African Americans," and "Post newsletters in African
American communities." The nonparticipant group specified, "Research about
the test not just from African Americans but whomever has participated."
8. D em ographic Characteristics

a) Gender- The majority of the respondents overall were female. Likewise, the
majority of the respondents in both the participant and nonparticipant groups
were female. The two variables (whether or not they participated and gender)
were not significant, indicating that the two variables were independent
b) Age- The largest number of respondents was in the 46-55 year age group.
Likewise, the largest number o f respondents in the participant group was in the
46-55 year age group, while the largest group of respondents in the
nonparticipant group was in the 36-45 year age group. The nature of the
association between the two variables (whether they participated and age) were
significant, indicating that the variables were not independent.
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c) Marital Status- Approximately half of the respondents were married.
Likewise, approximately half of the respondents in both the participant and
nonparticipant groups were married. In comparing the participant group to the
nonparticipant group, the two variables (whether they participated and marital
status) were not significant, indicating that the two variables were independent.
d) Education Level- The largest group of respondents overall and in both the
participant and nonparticipant groups completed 1-3 years college/
business/technical school. In comparing the participant group to the
nonparticipant group, the two variables (whether they participated and
education levels) were significant, indicating that the variables were not
independent.
e) Employment Status- The majority of respondents in both the participant and
nonparticipant groups were employed full time. In comparing the participant
group to the nonparticipant group, the two variables (whether they participated
and employment status) were not significant, indicating that the two variables
were independent.
f) Household Income- Overall, the largest group of respondents had a house-hold
income in the range of $20,000 - $29,999 per year. The largest number of
respondents in the participant group reported an approximate household
income range of $70,000 and over per year, while the largest number of
respondents in the nonparticipant group reported an approximate household
income in the range of $20,000 - $29,9999 per year. In comparing the
participant group to the nonparticipant group, the two variables (whether they
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participated and household income) were not significant, indicating that the
two variables were independent.
g) Distance from Respondents Domicile to Research Center- The largest group of
respondents overall and in both the participant and nonparticipant groups live
within IS miles o f the research center. In comparing the participant and
nonparticipant groups, the two variables (whether they participated and
distance lived from the research center) were not significant, indicating that the
two variables were independent.
h) Distance from Respondents Worksite to the Research Center- The largest
group of respondents overall and in both the participant and nonparticipant
groups work within 7 miles of the research center. In comparing the
participant and nonparticipant groups, the two variables (whether they
participated and distance worked from the research center) were significant,
indicating that the two variables were not independent.
i) Overall Health Status- The largest group of respondents overall and in both
the participant and nonparticipant groups were in good health. In comparing
the participant and nonparticipant groups, the two variables (whether they
participated and overall health status) were not significant, indicating that the
two variables were independent
9. The D iscrim inant Analysis Model- The factors attributable to the success
of this model were 1) knowledge factor "Awareness," 2) disadvantage factor
"Drawbacks," 3) "Did you receive any verbal or written materials that described
what the clinical trial was about and what you would need to do" (whether or not
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they responded "Yes"), 4) whether or not their marital status was Widowed, 5)
whether or not they were in the 26-35 year age group, 6) whether or not they were
in the 46-55 year age group, and 7) whether or not their place of employment was
within 15 miles of the Pennington Center. As a result, this model correctly
classified seventy five percent of the cases analyzed, which exceeded the minimum
requirement The Post Hoc Tau test statistic further supported the model as
meaningful in yielding almost double the minimum value required.
Conclusions. Implications, and Recommendations
1.

African Americans who are potential participants in clinical research trials have
high levels of knowledge in the dimension of awareness of issues surrounding
clinical research trials.

This conclusion is based on the finding that the mean score for African Americans on the
knowledge dimension labeled by the researcher as “Awareness” was 4.42 on a five-point
scale. This finding suggests that African Americans were aware of their right to change
their mind at any time and withdraw from a clinical trial and they can refuse to partici
pate. This finding further indicates that the research center is clearly conveying the
message that participation in a clinical research trial is voluntary to potential African
American participants.
Based on this conclusion and these findings the researcher recommends that the
Principal Investigator and research team o f clinical research trials which focus on African
Americans place an increased emphasis on issues that would potentially increase volun
tary participation of African Americans in clinical research trials. Some of the ways this
might be accomplished include: increasing the involvement of members of the research
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team in recruitment activities. The literature suggest that Investigators would do well to
solicit and incorporate the suggestions of African American community members and
potential participants in designing research protocols and recruitment strategies (CorbieSm ithetal., 1999).
2.

African Americans who have been participants in a clinical research trial have
higher levels of knowledge regarding clinical research trials than those who
have not participated.

This conclusion is based on the findings that the participant group have higher levels of
knowledge on both the “Awareness” (t 3g4= 4.093, g < .001) and the “Information
Provided” (t 3M= 4.943, g < .001) sub-scales of the knowledge scale than did the non
participant group. Providing the information necessary for a decision to participate or
not participate in a clinical research trial is supported by another study which showed
that African Americans were interested primarily in being educated about the study and
that lack o f information was a primary reason they did not participate in clinical trials
(Roberson, 1994). In addition, African Americans in another study requested broader
education about the importance o f and opportunities for participation in medical
research (Corbie-Smith et al., 1999).
Based on this conclusion and these findings the researcher recommends that the
Principal Investigators and research team of clinical research trials which focus on
African Americans place an increased emphasis on education about clinical research trials
in the African American community. Some o f the ways this might be accomplished
include: informational meetings through workshops and seminars to build trust through
first acknowledging the abuses surrounding previous clinical research trials. This may
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prove to create an opportunity for dialogue to heal the breached trust represented by the
Tuskegee Syphilis Study. The informational meetings should be held in African Ameri
can neighborhoods to include churches, community centers, state and local public meet
ings, and colleges or universities.
3.

African Americans who have participated in a clinical research trial have more
positive perceptions o f the “Participation Benefits” o f clinical research trials
than those who have not participated.

This conclusion is based on the finding that the participant group more strongly agreed
with the items in the factor “Participation Benefits” than did the nonparticipant group.
The mean score for the participant group was 4.39 (SD = .54) and for the nonparticipant
group 4.19 (SD = .62) (t 384= 3.249, g < .001). Studies have shown that the belief in the
benefit of participation is an indication that racial/ethnic groups are likely to be influ
enced to enroll in clinical research trials with some assurance that treatment could
improve survival (Roberson, 1994). Other investigators have shown that participants
expect to obtain personal benefit while contributing knowledge to medical science for the
good of society (Blumenthal, Sung, Coates, Williams, & Liff, 1995; Mattson, Curb, &
McArdle, 1985; Robinson, Ashley, & Haynes, 1996).
Based on this conclusion and these findings the researcher recommends that the
Principal Investigators and the research team o f clinical research trials which focus on
African Americans place an increased emphasis on publishing the results of all clinical
trials whether successful or unsuccessful. This will serve the purpose of building addi
tional trust, increasing awareness and providing information that will inevitably enhance
recruitment of African Americans in clinical research trials. Some of the ways to publi123
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cize the results o f a clinical trial include: production of research final report summaries
written in lay terminology, culturally sensitive, and published regularly in outlets that
reach the African American community.
4.

African Americans who have participated in a clinical research trial have more
positive perceptions regarding the advantages of clinical research trials than
those who have not participated.

This conclusion is based on the finding that the participant group more strongly agreed
with the items in the factor “Primary Benefits” than did the nonparticipant group. The
mean score for the participant group was 4.03 (SD = .60) and for the nonparticipant
group 3.83 (SD = .61) (t m = 3.179, j> = .002). Studies have shown that the perceived
benefits of clinical research trial participation, medical monitoring and treatment (Aby,
Pheley, & Steinberg, 1996; Cunny & Miller, 1994; Tangrea, Adrianza, & Helsel, 1992;
Wilcox & Schroer, 1994) altruism (Aby et al., 1996; Cunny et al., 1994) and financial
compensation (Bigorra & Banos, 1990; Cunny et al., 1994) were described by
participants as important.
Based on this conclusion and these findings the researcher recommends that the
Principal Investigators and research team of clinical research trials which focus on
African Americans, place an increased emphasis on the benefits o f participation in clinical
research trials. The participant group in this study supported this increased emphasis by
indicating “Other” perceived advantages for the individual of participation in clinical
research trials. Some of the “Other” perceived advantages included: “Leam about
medicine and body,” “Lose weight, medical exam,” and “aid research by being available.”
These “Other” perceived advantages are seen as benefits to the individual of participation
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in clinical research trials. The perceived benefits of clinical research trials are further
indicated by the nonparticipant group in this study. Some of the “Other” perceived
advantages from the nonparticipant group included: “Knowledge obtained is beneficial,”
“If clinical research trial helps find a cure for a particular disease,” and “Providing the
proper information; discussing the Phase I, II, III, IV trial results and expected
outcomes. Clients need to know all expectations and consequences.”
These “Other” perceived advantages by both the participant and nonparticipant
groups indicated that the message from Principal Investigators and the research team of
clinical research trials should be clear and focused such as, the results of the clinical
research trial indicated a decrease in cholesterol levels, blood pressure, blood sugar, and
weight loss.
S.

African Americans who have not participated in a clinical research trial more
strongly agreed with potential disadvantages to the individual of participation
in clinical research trials than those who have participated.

This conclusion is based on the finding that the nonparticipant group more strongly
agreed with the items in the factor “Drawbacks” than did the participant group. The
mean score for the nonparticipant group was 3.16 (SD = .90) and for the participant
group 2.65 (SD = .87) (t 384= -5.595, j> < .001). “Experiencing side effects of the
treatment” was the item with which nonparticipants most strongly agreed.
Based on this conclusion and these findings the researcher recommends that Princi
pal Investigators and research team of clinical research trials which focus on African
Americans participate in all procedures required by the trial. If the research team mem
bers have taken part in the clinical research trial processes and procedures they will have
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increased credibility and trust among African American participants. Studies have shown
that a trusting relationship was important for African Americans to feel comfortable as
participants in clinical studies (Corbie-Smith et al., 1991). Other authors have suggested
that trust developed between a primary care provider and a patient is the only way fear
of exploitation in research can be overcome (El-Sadr & Capps, 1992) and that lack of
trust in the researcher is the primary barrier to African American participation in clinical
trials (Mouton, Harris, Rovi, Solorzano, & Johnson, 1997). The nonparticipant group in
this study supported this increased emphasis by indicating “Other” perceived disadvan
tages for the individual of participation in clinical research trials. Some of the “Other”
perceived disadvantages included: “Risk to your health,”“Overcoming past atrocities
where African Americans were deliberately infected (i.e. syphilis virus),” and “Uncer
tainty of integrity of researchers/study.”
These “Other” perceived disadvantages by both the participant and nonparticipant
groups indicated that “Trip to clinic,” “Dates and times can’t be changed or rescheduled,
inconvenient,” and “No benefits if in control group” sends a clear message to Principal
Investigators and the research team of clinical research trials indicating that flexibility of
clinic hours as well as location of additional research sites other than at the research
center may prove to enhance recruitment and retention of potential African Americans
for participation in clinical research trials.
6.

African Americans who have participated in clinical research trials and received
verbal or written materials that described what the clinical trial was about and
what was needed are more likely to participate in future clinical research trials.
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This conclusion is based on the results obtained through comparison of mean values for
discriminating variables by participation status among African Americans. The results of
the one way analysis of variance (F3II,p < .01) was highly significant in the model
suggesting that increased participation in clinical research trials was based on African
Americans receiving verbal or written materials describing what the clinical trial was
about and what was needed. The literature coincides with this conclusion in that novel
methods of transmitting information such as instructional videos alone, or in combination
with the written form, have been shown to be preferred by patients (Agre, McKee,
Gargon, & Kurtz, 1997).
Based on this conclusion and these findings the researcher recommends that Princi
pal Investigators and research team of clinical research trials which focus on African
Americans produce effective and innovative presentations culturally sensitive to include:
graphics that illustrate the purpose, procedures, time commitments, benefits, and incen
tives for participation. Studies have shown that people might be retained for clinical
trials if they are informed, educated, and counseled (Roberson, 1994).

This may also

increase trust among African Americans especially if they feel as a result of participation
in clinical research trials, that their contribution to the study was valuable.
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APPENDIX A
LETTER OF INTRODUCTION
Dear Mr./Ms.
My name is Betty Kennedy. I am a Research Recruiter and graduate student in the
School of Vocational Education at Louisiana State University, Baton Rouge, Louisiana.
As a Research Recruiter at the Pennington Biomedical Research Center for seven years,
the task of recruiting African Americans into clinical trials remains a challenge. Since
African Americans are disproportionately affected and have a higher prevalence o f high
blood pressure, diabetes, and obesity, the goal to enroll African Americans into clinical
trials is crucial, especially finding ways to delay or prevent these diseases from occurring.
Therefore, I need your help so that I can become more precise and efficient at recruiting
African Americans into clinical trials. I am conducting a study to determine the reasons
African Americans do and do not participate in clinical research. The purpose of this
study is to gain an understanding of the knowledge, attitudes, and beliefs African
Americans have that either support their decision to participate or not participate in a
clinical trial. The findings from this study may improve the recruitment of volunteers in
future clinical research.
Your participation in this study will involve completing the enclosed questionnaire. It
will take no more than 20 minutes for you to complete. Please do not put your name on
the questionnaire or the return envelope. Ail replies will be kept confidential. No names
will appear on the questionnaire, only a code number.
Participation in this study is strictly voluntary and returning the completed
questionnaire will imply your consent. The responses will be stored in a locked filing
cabinet under my control. The information that you provide will not be used for any
purpose except for this study.
If you agree to participate, please complete and seal the questionnaire in the selfaddressed stamped envelope provided. If you have any questions about this
questionnaire, please contact me or my dissertation chair at the telephone numbers listed
below. A copy of the completed study will be available at the School of Vocational
Education (Old Forestry Building).
PLEASE RETURN THE COMPLETED QUESTIONNAIRE by: October 16,2009
Thank you in advancg, for your assistance in completing
questio.
eting this questionnaire.
Betty Kennedy, MPA, Ph.D. Candidate
Research Recruiter
Pennington Biomedical Reses irch Center
6400 Perkins Road
Baton Rouge, Louisiana 708! >8-0025
(225) 763-3090

Dr. Geraldine Holmes
Associate Professor, Dissertation Chair
Louisiana State University
127 Old Forestry BIdg.
Baton Rouge, Louisiana 70803
(225) 388-2464
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APPENDIX B
PERCEPTIONS OF PARTICIPATION IN CLINICAL RESEARCH
(MODIFIED McLean & Jensen, 1998)

The questions in this survey are about “clinical trials research”.
A “clinical trial” is a research study that can be used to answer questions about new
ways of both delaying and preventing diseases such as cancer, diabetes, heart disease,
high blood pressure, and obesity. Researchers obtain funding through federal, state, and
local means and generally utilize a research recruiter in obtaining volunteers to enroll in
the study.

Instructions for Completing the Questionnaire
Please read each question carefully. There are no right or wrong answers. Please
answer each question to the best of your knowledge. On a few questions, you will have
space provided so that you can write out a specific answer. For most o f the statements
you will be asked to select (1) strongly disagree, (2) disagree, (3) are unsure, (4) agree,
or (5) strongly agree. By selecting “strongly disagree” you are saying that you do not
believe or agree with the statement. By selecting “disagree” you are saying that although
you may not strongly disagree with the statement, you are still not 100% sure of i t By
selecting “are unsure” you are saying that you do not know. By selecting “agree” you
are saying that you don’t disagree with it. By selecting “strongly agree” you are saying
that you believe or agree with the statement. Please circle or check where applicable,
only one choice in response to each question or statement.

CONFIDENTIAL

THIS QUESTIONNAIRE CONTAINS 8 PAGES
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SECTION 1
The statements below are about your knowledge of clinical research. On a scale of 1-5,
do you (1) strongly disagree, (2) disagree, (3) are unsure, (4), agree or (5) strongly agree
as it relates to your knowledge o f clinical research. Please circle only one choice per
statement.
Strongly Disagree Unsure
Disagree

Agree

Strongly
Agree

1. Volunteers receive information
needed to decide whether they want
to take part in a clinical trial.

1

2

3

4

5

2. Volunteers can refuse to
participate in a clinical trial.

1

2

3

4

5

3. Volunteers can change their mind
at any time and withdraw from a
clinical trial.

1

2

3

4

5

4. Volunteers are made aware of any
possible complications or side effects
of taking part in a clinical trial.

1

2

3

4

5

5. Volunteers are told about the possible
risks and benefits of taking part in a
clinical trial.

1

2

3

4

5

6. Clinical trials are needed to study the
effects of treatments.

1

7. Volunteers usually receive a cash stipend
for participation in a clinical trial.
1
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SECTION n
The following statements are about your perceptions of clinical research. On a scale of
1-5, do you (1) strongly disagree, (2) disagree, (3) are unsure, (4) agree, or (5) strongly
agree as it relates to your perceptions of clinical research. Please circle only one choice
per statement.
Strongly Disagree Unsure
Disagree

Agree

Strongly
Agree

S. Clinical trials are a necessary
way to learn about treatments.

1

2

3

4

5

9. It is important for people to
take part in clinical trials.

1

2

3

4

5

10. The information in the consent
form is important to help volun
teers decide about participation
in a clinical trial.
1

2

3

4

5

11. Participation in a clinical trial
can help me and my family.

2

3

4

5

1

12. Participation in a clinical trial
can help future generations.
13. Blood work is necessary in a
clinical trial.
14. Participation in a clinical trial
can delay a disease.
15. Participation in a clinical trial
can prevent a disease.
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SECTION i n
Below is a list o f possible advantages and disadvantages of participating in a clinical
trial. Your answers are very important whether you participated or decided not to
participate in a clinical trial. On a scale of 1-5, do you (1) strongly disagree, (2)
disagree, (3) are unsure, (4) agree, or (5) strongly agree with the advantages and
disadvantages o f participating in a clinical trial. Please select only one choice per
statement.
Strongly Disagree Unsure
Disagree

Agree

Strongly
Agree

Advantages of Participation
16. Receiving the newest treatment.

2

3

4

5

17. Doing something that will help others.

2

3

4

5

18. Getting free medications.

2

3

4

5

19. Helping to delay a disease.

2

3

4

5

20. Helping to prevent a disease.

2

3

4

5

21. Doing something positive for self.

2

3

4

5

22. Getting a cash stipend.

2

3

4

5

Disadvantages of Participation
25. Being treated like a “guinea pig”.

2

3

4

5

26. Having to miss work.

2

3

4

5

27. Having to arrange childcare.

2

3

4

5

28. Losing one’s privacy.

2

3

4

5

23. Getting better care and follow-up
(for example, with laboratory tests)
24. Other advantages: (please
specify)____________________________

29. Experiencing side effects of the
treatment
30. Disrupting one’s normal daily routine.
31. Other disadvantages: (please specify)
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SECTION IV
The questions in this section are about participants’ and non-participants’ current and
past participation in clinical trials. Please check one appropriate choice.
32. Have you ever been asked to participate in a clinical trial?
1. YES □
2. NO □
33. Have you previously participated in a clinical trial?
1. YES □
2. NO □
34. Are you currently enrolled in a clinical trial?
1. YES □
2. NO □
35. If you said “No” to questions 32 through 34 above, and you were asked to
participate in a clinical trial in the future, would you participate?
1. YES □
2. NO □
36. Have you ever decided not to participate in a clinical trial after being eligible? If
no, go to Section V.
1. YES □
2. NO □
37. If yes, what is the primary reason that you decided not to participate in the
clinical trial? (Please check only one choice).
1. Changed jobs, schedule would not permit □
2. Changed mind, due to fear
□
3. Live too far from research center
□
4. Work too far from research center
□
5. Too much effort involved
□
6. Too many lab tests required
□
7. Other (please specify)_________________
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SECTION V
The next questions ask about who and what influenced your decision to participate or
not participate in a clinical trial. Your answers are important whether or not you decided
to participate in the trial. If you have been asked to participate in a clinical trial more
than once, please refer to the most recent time. Please check one appropriate choice.
38. Did you receive any verbal or written materials that described what the clinical trial
was about and what you would need to do?
1. YES
□
2. NO
□
3. UNSURE □
39. Did you talk to family or friends before making your decision to participate or not
participate?
1. YES
□
2. NO
□
3. UNSURE □
40. Did you talk to your doctor before making your decision to participate or not
participate?
1. YES
□
2. NO
□
3. UNSURE □
41. Did you have a family history of the disease being researched that prompted your
decision to participate or not participate?
1. YES
□
2. NO
□
3. UNSURE O
42. Other (please specify)
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SECTION VI
Below is a list of ideas/suggestions for ways to help people leam more about clinical
trials. Please indicate if you (1) strongly disagree, (2) disagree, (3) are unsure, (4) agree,
or (5) strongly agree that the statement is an appropriate means of helping people leam
more about clinical trials. Circle only one choice for each statement.
Strongly Disagree Unsure
Disagree

Agree

Strongly
Agree

43. Informational meeting about the
clinical trial, presented by the physician. 1

2

3

4

5

44. Informational meeting about the
clinical trial, presented by the nurse.

1

2

3

4

5

45. Informational meeting about the
clinical trial, presented by African
Americans.

1

2

3

4

46. Hearing about the good things that have
been discovered from clinical trials.
1

2

3

4

5

47. Talking to other African Americans,
who have taken part in clinical trials.

1

2

3

4

5

48. TV shows or videotapes with African
Americans in clinical trials.

1

2

3

4

5

5

49. Other suggestions: (please specify)_____________________________
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SECTION v n
This section asks for some general information about you. Please note that all
information is confidential. Your answers to the following questions will provide
useful and valuable information for this study. Please check only one appropriate
choice.
50. W hat is your gender?
1. MALE
2. FEMALE

□
□

51. W hat is your approximate age?
1.
2.
3.
4.
5.
6.

18-25 years
26-35 years
36-45 years
46-55 years
56-65 years
66 years and over

□
□
□
□
□
□

52. W hat is your marital status?
1.
2.
3.
4.

Married
Divorced/Separated
Never married
Widowed

□
□
□
□

53. Education (check the highest level completed)
1. Grades 0-8
2. Some High School
3. High School diploma/GED
4. 1-3 years college, business or technical school
5. College degree
6. Post graduate degree

□
□
□
□
□
□

54. What is your present employment status?
1. Employed M l time (at least 36.5 hrs/week)
2. Employed part-time (at least 20hrs/week)
3. Retired
4. Unemployed
5. Medical disability

□
□
□
□
□
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55. What is your approximate household income?
1. Less than $10,000 per year
2. $10,000 - $19,999 per year
3. $20,000 - $29,999 per year
4. $30,000 - $39,999 per year
5. $40,000 - $49,999 per year
6. $50,000 - $59,999 per year
7. $70,000 and above

□
□
□
□
□
□
□

56. Approximately how far do you live from the Pennington Center?
(Check the shortest distance that applies).
1.
2.
3.
4.
5.

Within 3 miles o f the research center
Within 7 miles of the research center
Within 15 miles of the research center
Within 20 miles of the research center
More than 20 miles from the research center

□
□
□
□
□

57. Approximately how far is your place of employment from the Pennington
Center? (Check the shortest distance that applies).
1.
2.
3.
4.
5.
6.

At the research center
Within 3 miles of the research center
Within 7 miles of the research center
Within 15 miles of the research center
Within 20 miles of the research center
More than 20 miles from the research center

□
□
□
□
□
□

58. In general, would you say your health is:
□
1. Excellent
□
2. Very Good
□
3. Good
□
4. Fair
□
5. Poor
Thank you for taking the time to complete the questionnaire!

Please seal this questionnaire in the self-addressed stamped envelope
provided and return by: October 16,2000.
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APPENDIX C
MODIFIED QUESTIONNAIRE APPROVAL

Subject: questionnaire
Dear Betty:
I have forwarded on Louise's response to you. My name is
mispeiled~it should read Donna McLean. I will forward a copy on to you
once we receive some copies. Good luck with your research. Keep us posted
we want to hear your comments of your experience.
Donna
---------------------- Forwarded by Donna McLean/UA/Nursing on 09/29/2000
04:53 PM --------------------------"Louise Jensen" <louise.jensen@ualberta.ca> on 09/27/2000 02:16:07 PM
To: donna.mclean@ualberta.ca
cc:
Subject: questionnaire
Hi Donna:
The modified version of the PPCR is fine with me. (Note that they spell
your name correct). The article is supposed to be coming out Vol 12, No 1
in Canadian Journal of Cardiovascular Nursing for them to reference.
However, I do not know the page number yet. Tell Betty that you will send
her a reprint as soon as you get them.
Louise
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APPENDIX D
PARTICIPANT RESPONSES
Question 24: Other Advantages
1. Learn about medicine and body. (9 responses)
2. Meeting others. (3 responses)
3. Don't know enough about this to make positive statements.
4. Lose weight, medical exam.
5. Aid research by being available.
Question 3 1: Other Disadvantages
1. Dates and times can't be changed or rescheduled, inconvenient (10 responses)
2. Forcing someone to overeat to maintain a specific weight; many studies are too long.
(5 responses).
3. Trip to clinic. (4 responses)
4. Not getting free medicine for other condition.
5. No benefits if in control group.
Question 37: Primary Reason Decided Not to Participate
1. Busy schedule. (4 responses)
2. Illness in family.
3. Was not selected.*
4. Didn’t lose weight.
*Each study has a different criteria; consequently, it’s possible to be eligible (selected)
for one study and not be eligible for another.
Question 42: Other Influences on Your Decision to Participate or Not
1. Having family history of disease. (17 responses)
2 .1 wanted to find out what research was about
3. Unemployed (needed money); wanted to help people by doing study.
Question 49: Other Ideas/Suggestions
1. More advertising in African American periodicals, TV commercials with African
Americans, post newsletters in African American communities. (9 responses)
2. Provide location for information and trial closer to individuals; have sites through out
city instead o f one location. (3 responses)
146

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

3. Flexible (longer) clinic hours: need to capitalize on first appointment because if people
have to wait 2 weeks or so to see a doctor to receive medication- then they have lost
their momentum/desire for losing weight or whatever reason for wanting to participate
in the study. (3 responses)
4. Let African Americans know how this can help them and their family. (2 responses)
5. Informational meeting about clinical trial presented by African American physician.
(2 responses)
6. To show how different foods react to humans as medicine for health and growth for
longlife.
7. Publish results.
8. Provide transportation.
9. Meet with health center; occupational therapy; outpatient therapy.
10. Reveal side effects.
11. Physician needs to have excellent interpersonal skills.
12. Hard for participants to change or transition into documentation part of a study;
seems to be a headache for the participant but needed for study. This needs to be
explained more so persons can accept this responsibility more willingly so that you
can get accurate and not made up data.
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APPENDIX E
NONPARTICIPANT RESPONSES
Question 24: Other Advantages
1. Knowledge obtained is beneficial. (11 responses)
2. If clinical trial helps find a cure for a particular disease. (5 responses)
3. Study more on sickle cell. (2 responses)
4. Providing the proper information; discussing the Phase I, II, III, IV trial results and
expected outcomes. Clients need to know all expectations and consequences.
5. New treatment not always an advantage.
6. Low-income families need more help.
7. Staff is trustworthy.
8. Getting a cash stipend for completing lengthy questionnaires.
Question 31: Other Disadvantages
1. Risk to your health. (11 responses)
2. Getting to clinic. (7 responses)
3. Time consuming; inconvenient. (4 responses)
4. Overcoming past atrocities where African Americans were deliberately infected (i.e.
syphilis virus). (3 responses)
5. Not knowing if you are receiving treatment or sugar pill. (3 responses)
6. Uncertainty of integrity of researchers/study.
7. Religious convictions.
Question 37: Primary Reason Decided Not to Participate
1. Disqualification; eligibility criteria for the study. (11 responses)
2. Hours of participation were during work hours. (9 responses)
3. No transportation.
4. Friend talked me out of it.
Question 42: Other Influences
1. Never asked to participate. (12 responses)
2. Did not fit profile. (12 responses)
3. To leam about health problem I had.
4. Financial need.
5. To help in scientific research.
Question 49: Other Ideas/Suggestions
1. Research about the test not just from African Americans but whomever has partici
pated. (6 responses)
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2. Congregations; ask East Baton Rouge (EBR) Ministers Association to participate;
have prominent African Americans of EBR community to do public service announce
ments; take clinical trials to churches, contact schools for volunteers. (3 responses)
3. Provide list of side effects. (3 responses)
4. Endorsements from patients’ Primary Care Physician (PCP) would lend credibility to
the trial. (2 responses)
5. Transportation, child care during screening visit, later appointments so that won’t
have to miss work. (2 responses)
6. Talking to people who had good experiences with the trials; give all information to
participants. (2 responses)
7. More TV commercials about clinic’s mission. (2 responses)
8. Explain how participation in clinical trials can possibly help you in prevention of a
disease.
9. Not having to be present daily to eat meals; meet for labs on weekends only; have
blood drawn at nearest hospital.
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